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Hepatocellular carcinoma (HCC) is the most commonly diagnosed form of liver cancer 
with high morbidity and mortality. Copy number variation analysis (CNV) of human HCC 
revealed that over 50% of the HCC samples examined had CNV in the gene leukocyte specific 
protein-1 (LSP1).  LSP1, a F-actin binding protein, is expressed in hematopoietic cells and 
interacts with Kinase Suppressor of Ras (KSR), a scaffold for the ERK/MAPK pathway. The 
expression of LSP1 in liver and its role in normal hepatocellular function and carcinogenesis 
remains unknown.  Therefore, LSP1 mRNA and protein levels were analyzed in normal 
hepatocytes in culture, rat liver following partial hepatectomy (PHx), and hepatoma cell lines.  In 
culture and after PHx, LSP1 increased after the termination of hepatocyte proliferation and 
migration. To investigate LSP1 function in HCC, shRNA was utilized to stably knock down 
LSP1 expression in the JM1 rat hepatoma cell line. Loss of LSP1 in JM1 cells resulted in 
dramatic upregulation of cyclin D1 and pERK2, as well as increased cell proliferation and 
migration.  Co-immunoprecipitation and immunofluorescence analysis displayed an interaction 
and co-localization between LSP1, KSR and F-actin in the JM1 cells and liver during 
regeneration. Conversely, expression of LSP1 in JM2 rat hepatoma cell line led to decreased 
proliferation. Enhanced expression of LSP1 in mouse hepatocytes during liver regeneration 
following injection of an LSP1 expression plasmid also led to decreased hepatocyte proliferation, 
cyclin D1 and pERK expression. LSP1 knockout mice subjected to PHx displayed increased 
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hepatocellular proliferation on day 4 when compared to control livers as well as increased pERK 
expression, whereas LSP1 overexpressing transgenic mice (TG) livers displayed a decrease in 
Ki67 positive hepatocytes on day 4 following PHx and decreased pERK expression. Hepatocytes 
from KO mice displayed increased proliferation in the absence of growth factors in culture 
whereas TG hepatocytes proliferated significantly less than WT control hepatocytes. Conclusion: 
LSP1 is expressed in normal hepatocytes and liver following PHx after the termination of 
proliferation. In rat hepatoma cell lines and mouse liver in vivo, LSP1 functions as a negative 
regulator of proliferation and migration. Given the high frequency of LSP1 CNV in human HCC, 
LSP1 may be a novel target for diagnosis and treatment of HCC. 
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really think about and understand the experiments. My committee members: Dr. Donna Stolz, 
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that I have made you proud. To the rest of my family and friends: I love you all and truly 
appreciate all that you have done to support me throughout the years.   
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1.0  INTRODUCTION 
1.1 THE LIVER AND REGENERATION 
1.1.1 The liver: its functions and architecture 
The liver is a unique organ with a phenomenal ability to regenerate and perform a variety of 
complex functions. One function of the liver is to detoxify the blood of chemicals found in food 
delivered from the small and large intestine, the spleen and pancreas.. Liver reprocesses the 
nutrients from food into secreted proteins such as albumin, coagulation factors and proteins that 
comprise plasma in the peripheral blood. The liver also produces lipids, which are sent to other 
tissues as lipoproteins, and carbohydrates stored as glycogen, which function to stabilize glucose 
levels in the blood.  In addition to the previously stated functions, hepatocytes synthesize bile, 
which is secreted from the apical side of the hepatocyte into the bile canaliculi that lines the area 
between hepatocytes and coalesces into the bile duct, which are lined with cholangiocytes. Bile 
is crucial for absorption of fat and other lipophilic nutrients in the small intestine. The liver also 
acts as the main regulator of ammonia and glucose levels in the blood, which affect normal brain 
functions. Without a functioning liver, hepatic encephalopathy can occur, which eventually leads 
to coma and death (1-3).   
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The liver is a highly specialized tissue consisting of a variety of cell types, which include 
hepatocytes, cholangiocytes (biliary cells), hepatic stellate cells, Kupffer cells, and sinusoidal 
endothelial cells. In development, hepatocytes, the main functional cell of the liver, and 
cholangiocytes, the cells that line the bile ducts, are derived from a common precursor cell, 
which is known as the hepatoblast. Having a common precursor cell allows hepatocytes and 
cholangiocytes to transdifferentiate in response to injury when one cell type cannot replicate to 
replace the lost cells (4, 5) The non-parenchymal cells (NPC) of the liver consist of hepatic 
stellate cells, sinusoidal endothelial cells, and Kupffer cells. The hepatic stellate cell is a 
mesenchymal cell that functions in vitamin storage, turnover of extracellular matrix, secretion of 
growth factors such as HGF, and vascular tone among others and is located in the area between 
the hepatocytes and sinusoidal endothelial cells, which is known as the space of Disse. Injury to 
the liver results in the activation of stellate cells to become myofibroblast like cells, which are 
contractile and secrete extracellular matrix proteins. Hepatic stellate cells share a gene 
expression profile very similar to the astrocytes of the brain (2, 6, 7). Sinusoidal endothelial cells 
have fenestrations, which are large cytoplasmic gaps that allow for the movement of 
macromolecules and lipoproteins into and out of the hepatocytes and blood. Kupffer cells, the 
resident macrophages of the liver, play a role in immune functions in the liver (Figure 1A) (2, 8). 
Hepatocytes form cords along a specialized capillary bed lined with fenestrated 
sinusoidal endothelial cells.  Blood flows into the liver in a unidirectional manner from the portal 
vein and hepatic artery through the sinusoids to the central vein, which unites with the hepatic 
vein and finally connects with the inferior vena cava. The liver is organized into hepatic lobules, 
which are hexagonal units that consist of cords of hepatocytes, the parenchymal cells of the liver, 
branching out from a central vein. The hepatic artery and portal vein along with the collecting 
 3 
bile duct form the portal triad, which is found at the corners of the hepatic lobule. Each lobule 
consists of three broad zones: periportal (zone 1), transitional (zone 2), and pericentral (zone 3). 
Proceeding from Zone 1 to Zone 3, hepatocytes are exposed to rising levels of processed 
xenobiotics and toxins and decreasing levels of oxygen (Figure 1B) (2, 9, 10).  
 
 
 
 
 
Figure 1. Liver Architecture. (A) Schematic depicting the hepatic sinusoid architecture and cell 
types. Blood flows into the lobule through the portal vein (PV) and hepatic artery (HA) and then into the 
capillaries, ending at the central veins (CV). Bile moves away from the central vein towards the portal triad 
and leaves the lobule through the bile ducts (BD). Hepatocytes form “plates” 1-2 hepatocytes thick along the 
sinusoids. In the “space of Disse” which is the area between the sinusoidal endothelial cells and hepatocytes, 
the hepatic stellate cells reside. (B) Schematic showing hepatic lobule organization, including the structure of 
the vasculature and lobule zonation. This structure occurs throughout the liver. Hepatocyte plates are shown 
for orientation; the entire lobule would contain these plates of hepatocytes and be lined with sinusoids. 
Adapted from (2). 
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1.1.2 Liver regeneration 
The liver has a unique capacity to regenerate after a loss of liver mass. Liver regeneration is a 
highly complex and organized process, which under normal conditions involves all of the cells of 
the liver undergoing one to three rounds of replication in order to restore the original number of 
cells and overall mass of the liver. Hepatotoxic chemicals, such as carbon tetrachloride, can be 
administered to induce a loss of liver mass. However, this form of injury results in an 
inflammatory response to remove tissue debris followed by the regenerative process. The most 
common model to study liver regeneration is the 2/3 partial hepatectomy (PHx) model in which 
2/3 of the liver mass is removed surgically (11). Three of the five lobes of the rodent liver are 
removed without damaging the remaining two lobes, which grow to restore the mass of the 
original five lobes. The regenerative process is complete within 5-7 days following surgery. 
Partial hepatectomy is the preferred model for the experimental study of liver regeneration due to 
its reproducibility in terms of the mass removed and the accuracy of the events that ensue after 
the procedure. This model is also utilized in a clinical setting in humans to remove primary liver 
cancer, metastases from other organs or following trauma. However, the main disadvantage of 
the PHx model is its limited applicability to study liver regeneration in humans, which involves 
inflammation and necrosis  (1, 7, 12-14). 
PHx initiates a series of events that progress in a systematic way and can be observed 
from 5 minutes after the procedure to 5-7 days. The first cells to undergo DNA synthesis are the 
hepatocytes. DNA synthesis peaks at 24 hours post PHx in the rat and approximately 36 hours 
post PHx in the mouse (Figure 2). After the first round of replication, a second smaller 
population of hepatocytes replicates to restore the original number of cells. Hepatocyte 
proliferation occurs as a wave of mitoses, beginning at the periportal area and moves toward the 
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pericentral area of the lobule (15). The last hepatocytes to undergo DNA synthesis are the ones 
around the central vein, which are positive for glutamine synthetase (16). At the end of 
proliferation, a small number of hepatocytes undergo apoptosis to correct for any extra 
hepatocytes and restore the mass of the liver to its original size (17). Hepatocytes secrete growth 
factors and cytokines that stimulate the other cell types of the liver to undergo proliferation. 
Biliary epithelial cells and stellate cells begin to proliferate about 12 hours after the hepatocytes 
with a peak of DNA synthesis at about 48 hours in the rat. Endothelial cells begin to proliferate 
2-3 days post PHx and finish at 4-5 days. The liver is organized into cell clusters containing 10-
14 hepatocytes on day 3 after PHx. On Day 4, the stellate cells send processes into the 
hepatocyte clusters and start to produce laminin. Next, the sinusoidal endothelial cells penetrate 
the hepatocyte clusters and restore the normal liver vasculature. Restoration of normal liver mass 
is complete between 5-7 days post PHx in rodents (in humans, 8-15 days) and is due to the 
replication of mature adult hepatocytes and other hepatic cells and not by the proliferation of a 
small population of stem cells. The size of the liver lobules is larger and the hepatocyte plates are 
almost twice as thick as the original one cell thickness after regeneration. For several weeks 
following regeneration, lobule reorganization takes place and eventually the histology of the 
liver is identical to the original liver (1, 7). Since partial hepatectomy is a form of liver injury, it 
is not unexpected that the same signaling pathways occurring during liver regeneration also play 
a role in the wound healing process that occurs in other tissues (1).  
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1.1.3 Signaling mechanisms involved in the initiation of liver regeneration after partial 
hepatectomy 
PHx activates the expression of a large number of genes and a sequence of cellular events that 
are tightly regulated. One of the earliest biochemical events that occur after PHx is an increase in 
the activity of urokinase plasminogen activator (18), which occurs 5 minutes after PHx (19). uPA 
Figure 2. Kinetics of DNA synthesis in different cell types of the rat liver after partial 
hepatectomy. The four major cell types divide at different times during regeneration. 
Hepatocytes proliferate first with the peak of DNA synthesis occurring at 24 hours, whereas 
the other cell types proliferate later. Regenerating hepatocytes secrete growth factors that 
can stimulate the other cell types to undergo cell division. Adapted from (5). 
 7 
activation is associated with an increase in the activation of plasminogen to plasmin at 10  
minutes after PHx and fibrinogen degradation products. Urokinase initiates remodeling of the 
matrix, which is also seen in wound healing. Studies conducting on wound healing and tumor 
biology have demonstrated that matrix remodeling initiates integrin signaling along with 
releasing growth factors and peptides that are bound to the matrix and have signaling 
capabilities. Extracellular matrix regulation during liver regeneration is a complicated process 
involving matrix metalloproteinases and tissue inhibitors of metalloproteinases (20). In the 
extracellular matrix of the liver are many matrix bound growth factors, one of which is 
hepatocyte growth factor (HGF) (21). uPA activates matrix bound HGF by converting it into its 
active heterodimeric form. (19) At three hours post PHx, the amount of active and inactive HGF 
from pre-existing stores is diminished but plasma HGF levels rise by 10 to 20 fold. In the liver, 
HGF mRNA expression is increased in the stellate and endothelial cells and the lungs, kidney 
and spleen also produce increased levels of HGF (12). Within 30-60 minutes after PHx, active 
HGF leads to the activation of the HGF receptor Met. Although epidermal growth factor receptor 
(EGFR) is constitutively phosphorylated, there is an increase in EGFR phosphorylation at the 
same time as Met (22). EGF is secreted by the Brunner’s glands of the duodenum and is 
constantly available to the liver through the portal circulation. Studies have shown that cross talk 
occurs between cMet and EGFR and that Met activation may increase activation of EGFR after 
PHx. In addition to the increase in HGF expression in the circulation, there is also an increase in 
the amount of tumor necrosis factor (23), bile acids (24), interleukin-6 (25), serotonin (26), 
norepinephrine, hyaluronic acid (a main component of the matrix in the liver) and transforming 
growth factor βI (TGF βI) (1, 7). 
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Various molecular changes are occurring inside of the hepatocytes following PHx. 
Between 15-30 minutes following PHx, beta-catenin and Notch-I intracellular domain (NICD) 
are located in the nuclei of the hepatocytes (27, 28). Within one hour, there is increased Stat3 and 
NFκB activation. At six hours after PHx, cyclin D1, a protein involved in cell cycle dynamics, is 
activated in the hepatocytes and amino acids and TOR regulate this activation. On days 2 and 3 
after PHx, there is a decrease in the ratio C/EBPα to C/EBPβ, which is believed to play a role in 
enhancing the synthesis of lipids by hepatocytes. The alterations in gene expression patterns that 
occur during liver regeneration are reliant on both cytokine and growth factor signaling. (1, 12, 
13) 
Two of the main signaling molecules that are involved in the initiation of liver 
regeneration are HGF and the ligands of EGFR. HGF, along with the EGFR ligands (EGF, 
TGFα, Amphiregulin, HB-EGF, etc.), are the only direct mitogens for hepatocytes, meaning they 
cause a strong mitogenic response in hepatocytes in culture as well clonal population expansion 
in the absence of other factors. Injection of HGF, EGF, and TGFα into mice and rats leads to 
proliferation of hepatocytes and subsequently, enlargement of the liver. Additionally, other 
substances, such as TNF, norephinephrine, and estrogen, while not direct mitogens, can increase 
the effect of the direct mitogens and enhance proliferation. (1, 7, 12) 
1.1.4 Signaling mechanisms involved in the termination of liver regeneration following 
PHx 
Termination of liver regeneration is also a highly controlled complex process of which much less 
is known. Liver mass is highly regulated returning to prehepatectomy mass with great accuracy 
following regeneration. To correct for inappropriate proliferation, there is a small amount of 
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hepatocellular apoptosis that occurs at the end of regeneration (17). A recognized inhibitor of 
hepatocyte proliferation is TGFβI and its expression increases within five hours after PHx and 
remains increased until the end of regeneration (29, 30). However, overexpression of TGFβI in a 
hepatocyte specific transgenic mouse causes elevated levels of TGFβI in the blood but does not 
have an effect on liver regeneration. Activin, a cytokine, is also known to inhibit hepatocyte 
proliferation and inactivation of its receptor along with inactivation of TGFβI receptor leads to 
prolonged regeneration. Another piece of evidence to demonstrate a role for TGFβI in 
regeneration is that injection of a dominant negative TGFβI receptor into unoperated mice led to 
stimulation of hepatocellular DNA synthesis (31). This suggests that hepatocytes are under a 
“constant tonic antagonism” between HGF and TGFβI in the pericellular area around the 
hepatocytes. All of this suggests that termination of regeneration is a reverse of initiation in 
which the formation of extracellular matrix and decorin leads to the binding of HGF and TGFβI 
restoring the pre-hepatectomy balance in the pericellular space.  
Extracellular matrix plays an important role in the termination of liver regeneration. ECM 
not only stores a variety of factors that regulate growth, but also mediates signaling to the 
surrounding cells through integrins. Previous studies have demonstrated that when integrin 
linked kinase (32) expression is lost through genetic elimination in the liver, this leads to 
increased proliferation of hepatocytes and biliary cells in the absence of PHx (33). Following 
PHx, loss of ILK in the liver results in a termination defect in which the liver grows 59% larger 
than their pre-hepatectomy weights. These livers lacking ILK expression also expressed 
increased HGF as well as increased expression of Yap (Yes-associated protein) in the nuclei of 
hepatocytes, which is a protein involved in the regulation of organ size (34, 35). In vitro, ECM, 
in the form of matrigel or collagen gels, leads to an inhibition of proliferation with an increase in 
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hepatocyte differentiation (36). Therefore, ECM signaling through integrins plays an important 
role in the termination of liver regeneration.  
The complex ECM consists of a variety of components including proteins and 
glycosaminoglycans among others. Another component of the ECM that seems to play a critical 
role in liver regeneration termination is Glypican 3 (GPC3).  GPC3 is highly expressed in the 
pericellular area surrounding hepatocytes as well as other epithelial cells (37). GPC3 is the most 
overexpressed protein in human hepatocellular carcinoma (HCC) as well as in other tumors (38) 
and it is used as a marker of human liver cancer in clinical settings (39). In patients with 
Simpson-Gholabi-Behmel (SGB) syndrome, a loss of function deletion in GPC3 leads to 
organomegaly of the liver and other internal organs as well as bone and muscle enlargement 
(40). Although GPC3 is highly expressed in HCC, the loss of function of GPC3 in SGB leading 
to increased liver size suggests that GPC3 may act as a growth suppressor and in HCC is 
produced as a failed growth suppressor, which can no longer suppress tumor growth. Loss of 
GPC3 function in mice leads to similar symptoms to patients with SGB. (41) During liver 
regeneration, GPC3 expression increases towards the end of regeneration and loss of GPC3 
expression in hepatocytes in culture leads to enhanced proliferation. (42) In a transgenic mouse 
line expressing GPC3 specifically in hepatocytes, liver regeneration after PHx was suppressed 
and proliferation of hepatocytes was inhibited indicating that GPC3 functions as a growth 
suppressor in hepatocytes. (43) These findings demonstrate that the ECM plays a critical role in 
the termination of liver regeneration following PHx. 
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1.2 LIVER CANCER 
1.2.1 Types of liver cancer and statistics  
Liver cancer is one of the most common and lethal forms of cancer in the world. The term liver 
cancer consists of a variety of histologically diverse primary hepatic neoplasms, which includes 
hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (bile duct carcinoma), 
hepatoblastoma, bile duct cystadenocarcinoma, hemangiosarcoma, and epithelioid 
hemangioendothelioma. HCC, the most common form of primary liver cancer, accounts for 
approximately 80% of cases. The second most common form, cholangiocarcinoma, which is 
cancer of the bile duct cells, represents 10-20% of liver cancer diagnoses (44).  
According to the American Cancer Society, in the United States in 2016, there will be 
39,320 new cases of liver cancer diagnosed and approximately 27,170 people will die from this 
disease. Incidence of liver cancer in the United States has tripled from 1980. The relative five-
year survival rate for patients with liver cancer in the United States is relatively low at 15%. 
Liver cancer affects men more than woman with the lifetime risk for an average man being 1 in 
81 whereas for an average woman it is 1 in 196.  Throughout the world, more than 700,000 
people are diagnosed with liver cancer and it remains the leading cause for cancer deaths 
worldwide, with more then 600,000 deaths each year. Liver cancer is more common in sub-
Saharan Africa and Southeast Asia than in the U.S. (45). The high death rates associated with 
liver cancer are due in part to resistance to current anti-cancer therapies, limitations on the use of 
chemotherapeutics due to underlying liver conditions as well as a lack of biomarkers to detect 
liver cancer early (44). Many patients present with cancer symptoms when the cancer is in 
advanced stages, making it difficult to treat and resulting in death within 3-6 months (46). 
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1.2.2 Causes of liver cancer 
The majority of HCC patients have underlying liver cirrhosis. Chronic injury to the liver results 
in continual rounds of hepatocellular damage and regeneration leading to chronic liver disease. 
This can then develop into cirrhosis, which occurs when activation of stellate cells into a 
myofibroblast phenotype leads to deposition of fibrous tissue such as collagen I and loss of 
hepatocytes due to a decrease in the regenerative capacity of the liver. Over time, the cirrhotic 
nodules may develop genetic alterations and genomic instability resulting in HCC (47, 48). 
There are a variety of factors that increase the risk of developing cirrhosis and can ultimately 
lead to HCC, which includes hepatitis B and C viral infections, alcoholism, consumption of 
aflatoxin-contaminated foods, nonalcoholic steatohepatitis, diabetes, obesity, and certain 
hereditary conditions (44, 47, 49). Although cirrhosis infers a greater risk of developing HCC, 
the relationship between cirrhosis and hepatocarcinogenesis is complex and may involve a 
patient having a combination of etiologies (47). 
Viral induced hepatocarcinogenesis is associated with two main viruses, hepatitis B and 
C. Hepatitis B virus (HBV) is a partially double stranded DNA virus of the hepadnaviridae 
family that infects approximately 2 billion people in the world. Around 30-50% of HBV related 
deaths are due to HCC. Hepatitis C virus is a non-cytopathic RNA virus of the flaviviridae 
family. Approximately 170 million people are infected with HCV worldwide and 20% of these 
patients will develop cirrhosis and 2.5% of those will progress to HCC. HCV and HBV differ in 
three important ways in regards to HCC development. First, HCV is more likely to result in 
chronic infection than HBV with 60-80% of HCV cases versus 10% of HBV infected patients. 
Second, HCV infected individuals have a greater propensity to develop cirrhosis which is a 
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precursor to HCC. Lastly, HCV is an RNA virus without an intermediate DNA form so it is 
unable to integrate into the genome of the host (44, 50). 
Chronic alcohol intake is another risk factor for HCC development. Alcoholism causes 
activation of monocytes, which leads to increased production of pro-inflammatory cytokines as 
well as increased endotoxin in the circulation leading to hepatocyte death (51). Hepatocytes 
develop an increased sensitivity to tumor necrosis factor α (TNF α), resulting in a continuous 
cycle of hepatocyte death and regeneration, stellate cell activation, cirrhosis and HCC (52). 
Chronic alcohol consumption can also damage the liver through increased oxidative stress 
resulting in fibrosis and hepatocarcinogenesis (44). 
Another factor that imposes an increased risk for HCC development is ingestion of fungal 
toxin, aflatoxin B1. Aflatoxin B1 is a mutagen associated with a particular p53 mutation and 
activation of oncogenes, such as HRAS (53, 54). However, unlike viral and alcohol induced 
hepatocarcinogenesis, exposure to aflatoxin is not associated with development of cirrhosis 
suggesting that the toxin induced mutagenesis may be the primary driver of HCC (44).  
1.2.3 Liver carcinogenesis mechanisms 
Many molecular and genetic pathways are altered and contribute to hepatocarcinogenesis. One 
common genetic event that occurs in HBV, HCV, and aflatoxin B1 induced HCC is inactivation 
or mutation of the tumor suppressor protein, p53 (55). Inflammation, constant rounds of necrosis 
and regeneration, and oxidative stress are hallmarks of viral and alcohol induced HCC, 
indicating that these processes play a role in the development of HCC. The MAP kinase pathway 
is also activated in HBV and HCV infected livers suggesting its importance in 
hepatocarcinogenesis (56, 57). Molecular analysis of human HCC has demonstrated a variety of 
 14 
genetic and epigenetic alterations that occur in important oncogenes and tumor suppressor genes 
such as TP53, β-catenin, ErbB receptor family, MET receptor and its ligand hepatocyte growth 
factor (HGF), p16(INK4a), E-cadherin, and cyclooxygenase 2 (COX2), among others (44). 
In addition to genetic alterations in particular oncogenes and tumor suppressor genes, 
HCC is characterized by genomic instability. A key feature of chronic hyperproliferative liver 
disease is telomere shortening, which is thought to contribute to the induction of HCC (58). 
Telomerase is highly activated in ~90% of human HCC suggesting that this process facilitates 
HCC progression (59, 60). Studies utilizing TERC (essential RNA component of telomerase) 
null mice have demonstrated that dysfunction of the telomeres resulted in increased initiation of 
hepatic tumors whereas loss of telomerase activity inhibited progression of HCC (61). 
Chromosome segregation defects that occur during mitosis cause aneuploidy and an increase in 
HCC incidence (62). 
1.2.4 Treatments for liver cancer 
Treatment options for patients with HCC are limited and the prognosis for patients with 
advanced HCC remains poor (18). Approximately 30% of patients are eligible for curative 
treatments such as resection of the tumor, liver transplantation or local ablation, which results in 
5-year survival rates around 50% (63). Approximately 20% of patients can receive 
chemoembolization (64). Tumor resection is usually performed on patients with a non-cirrhotic 
liver with only one tumor.  Liver transplantation mainly helps patients with decompensated 
cirrhosis and either one tumor less than 5 cm or three small tumors less than 3 cm in diameter 
(63). The drawback to transplantation is that the shortage of donor livers severely limits its use to 
treat HCC (63). Percutaneous treatments are utilized in patients with early HCC that is unable to 
 15 
be resected (63). There are a variety of methods to kill tumor cells in the liver including 
chemically by using ethanol or acetic acid and by changing the temperature of the cells through 
radiofrequency, microwave, laser, and cryoablation (65). Arterial embolization is utilized in 
patients with unresectable HCC in which gelatin is administered along with intra-arterial 
chemotherapy, most commonly doxorubicin, mitomycin, and cisplatin, along with lipiodol. In 
approximately 15-55% of patients, this method can achieve partial results and delays progression 
of the tumor and invasion of the vasculature (66, 67).  
The only molecular targeted therapy that is FDA approved to treat advanced HCC is 
sorafenib. Sorafenib is an oral inhibitor of multiple tyrosine kinases as well as an angiogenesis 
inhibitor that is active against vascular endothelial growth factor (VEGF), platelet derived 
growth factor receptor (PDGFR), c-KIT receptor, BRAF and p38 signaling pathways (18). 
Patients with advanced HCC taking sorafenib have a median time to disease progression of 5.5 
months and median overall survival of 10.7 months (68). Sorafenib significantly improved 
overall survival in comparison to placebo in two large phase III trials (68, 69). There are 
currently no additional therapies for patients whose cancer progresses while taking sorafenib or 
are unable to tolerate this treatment (18). Since the efficacy of the currently available treatments 
is low, there remains a great need to develop novel therapeutics to treat HCC.  
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1.3 GENETIC ABNORMALITIES IN LIVER CANCER 
1.3.1 Copy number variation analysis and gene expression profiling in HCC 
Global gene expression profiling of HCC is utilized to identify novel therapeutic targets as well 
as to improve the prognosis and diagnosis of HCC by identifying genetic alterations in the 
tumors. Data from these studies provides vital information to characterize HCC into different 
molecular subgroups, which improves the selection of specific treatments and overall outcome 
for patients with HCC. DNA microarrays are utilized to analyze the expression of thousands of 
genes and can successfully predict prognosis as well as organize different types of cancer into 
specific molecular subgroups (70). Understanding the heterogeneity of HCC by utilizing 
genomic expression profiling will improve patient response to treatment because certain 
therapeutics will only be successful in particular subtypes of the disease (70, 71).   
Several recent studies have identified large deletions and point mutations as well as copy 
number variations, meaning genome amplifications and deletions of a large size in HCC. One 
study identified alterations in four genes not previously described in HCC. One of these genes 
IRF2 has potential tumor suppressor properties and when inactivated leads to impairment of 
TP53 function in HBV related tumors (72). Exome sequencing of HCC lead to the identification 
of 161 potential driver mutations, which are associated with 11 pathways that are altered in HCC 
(73). 
A recent publication from our laboratory focused on identifying CNVs of a small size 
unlike other recent studies, which focused on large CNVs (74). The rationale is that important 
small CNVs would be missed in a study that only detects large CNVs, which would be likely to 
have many genes in each CNV. This would make it difficult to determine which genes in the 
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CNV are promoting hepatocarcinogenesis. In our study, LSP1 was the most frequent CNV 
detected in HCC (51 out 98 human HCCs sampled). All of the CNVs (5 amplifications and 46 
deletions) affected the C-terminal region of the gene, which contains the F-actin binding domain 
of LSP1 (Figure 3). Deletions of LSP1 along with KIAA1217 were associated with larger tumor 
size in comparison to tumors lacking these deletions. LSP1 has not been studied in liver biology 
and therefore no known role for LSP1 in liver exists. Since greater than 50% of tumors have 
CNV in the LSP1 gene it is important to determine if LSP1 plays a role in normal hepatocellular 
function as well as in carcinogenesis (74). 
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Figure 3. Genomic mapping of LSP1 deletions (blue) and 
amplifications (red).  Vertical Bars represent exons and horizontal bars 
represent introns. The minimal number of markers utilized for 
detection is indicated as well as p values. All LSP1 CNVs affect the C-
terminal region of the gene. Adapted from (71) 
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1.4 LEUKOCYTE SPECIFIC PROTEIN-1  
1.4.1 Structure, expression and basic functions of LSP1 
Leukocyte specific protein-1 (LSP1), an F-actin binding protein, is expressed in lymphocytes as 
well as macrophages, neutrophils and endothelial cells (75). LSP1, a 339 and 330 amino acid 
protein in humans and mice, respectively, is composed of two distinct domains, the acidic N-
terminal region, which contains two putative calcium EF hand motifs, and the basic C-terminal 
region, which contains the F-actin binding region of the protein as well as serine and threonine 
phosphorylation sites. These sites are phosphorylated by MAPKAP2 (MK2) at serines 195 and 
243 and protein kinase C (PKC) at serines 202 and 283 of the mouse LSP1 (Figure 4) (75, 76). 
The LSP1 c-terminal region also binds to PKCβI, targeting it and the ERK/MAPK pathway to 
the cytoskeleton. LSP1 binds to F-actin between amino acid residues 300-330 with a high 
affinity (Kd= 0.2μM) (77). LSP1 does not play a role in actin polymerization kinetics nor does it 
directly bind to G-actin but it does facilitate bundle formation from polymerized F-actin 
filaments (76). 
LSP1 protein is highly conserved in humans and mice with 67% of the amino acid 
sequence identical. However, the majority of the identical sequences occur in the C-terminal 
region of the protein with 85% sequence homology whereas there is only a 53% homology 
between human and mouse LSP1 in the N-terminal region (2, (78).  
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The LSP1 gene in both mice and humans encodes different transcripts through alternative 
exon splicing. An alternate LSP1 related protein, S37, contains 328 amino acids and differs from 
LSP1 only in N-terminus of the protein with the beginning 23 amino acids of LSP1 replaced with 
21 different amino acids in S37 (79).The gene also contains a 3’ acceptor site in exon 5 resulting 
in transcripts that either have or do not have an 18 bp sequence that encodes for HLIRHQ amino 
acids. Whereas LSP1 is expressed in hematopoietic cells, S37 appears to be predominantly 
expressed in mesenchymal cells during mouse development. 
Figure 4. Schematic of mouse LSP1 protein structure. The N-terminal region comprises 
amino acids 1-178 and contains putative calcium binding sites. The C-terminal region consists 
of amino acids 178-330 and contains serine residues that are phosphorylated by MK2 (195 
and 243) and PKC (202 and 283). Amino acids 300-330 comprise the F-actin binding domain. 
Adapted from (72). 
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LSP1 is found predominantly on the cytoplasmic side of the plasma membrane in 
lymphocytes but can also be found in the soluble cytoplasm and attached to the F-actin 
cytoskeleton during chemotaxis (80). During chemotaxis, LSP1 localizes with F-actin in 
filopodia, lamellipodia and membrane ruffles of the neutrophils. In endothelial cells, LSP1 is 
located mainly in the nucleus with low levels of the protein interacting with the F-actin 
cytoskeleton.  LSP1 co-localizes to F-actin aggregates with anti-IgM induced B cell receptor 
caps in B cells (75). 
1.4.2 Role in leukocyte and endothelial biology 
The main function of LSP1 is regulating cellular migration and chemotaxis.  LSP1 negatively 
regulates the migration of leukocytes and this regulation is dependent on the level of LSP1 
interacting with F-actin. High levels of LSP1 bound to F-actin microfilaments leads to decreased 
leukocyte movement. Utilizing a LSP1 knockout mouse model, two different models of 
inflammation were induced; the first involved injection of thioglycollate into the peritoneum and 
the second involved injection of zymosan into the knee joint. Loss of LSP1 lead to increased 
numbers of leukocytes migrating to the site of inflammation in the LSP1 deficient mice in 
comparison to wild type controls (81). Neutrophils from a patient with neutrophil actin 
dysfunction syndrome (NAD47/89), which express high levels of LSP1 in their neutrophils, 
displayed decreased motility in vitro (82, 83). Patients with NAD47/89 experience frequent 
severe infections due to neutrophils exhibiting impaired actin polymerization, chemotaxis 
induced by fMLP and capacity to kill bacteria (84). Expression of LSP1 in an LSP1 deficient 
melanoma and U937 monocyte cell lines also led to decreased motility and the formation of F-
actin bundle enriched hair like structures. The negative effect of LSP1 on U937 cell motility was 
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only observed in cells expressing LSP1 levels similar to that of neutrophils. Expression of lower 
levels of LSP1 actually led to increased migration in U937 cells in comparison to control cells 
(82, 85).  LSP1 is a negative regulator of leukocyte migration and its role in cellular motility is 
dependent on the level of LSP1 interacting with F-actin.  
The data on the role of LSP1 in leukocyte chemotaxis is conflicting. One group found 
that LSP1 deficient neutrophils displayed impaired chemotaxis in comparison to controls, which 
contradicts the previous findings that LSP1 negatively regulates leukocyte migration and 
chemotaxis (86). However, the role of LSP1 in migration is highly dependent on the type of 
integrin involved. Chemotaxis assays were performed with LSP1 -/- neutrophils on two different 
substrates, fibrinogen or fibronectin, in which loss of LSP1 only accelerated migration on 
fibrinogen. These results demonstrate that the role LSP1 plays in negatively regulating migration 
and chemotaxis is likely through adhesion to specific integrins such as Mac-1 (87). Studies have 
shown the intergrin Mac-1 is negatively regulated by LSP1 and that through inhibition of Mac-1, 
LSP1 also inhibits superoxide production in neutrophils induced with thioglycollate (86, 88). 
LSP1 both negatively and positively affects the chemotaxis of neutrophils depending on the 
integrins involved and the substrate on which the cells are migrating. 
In addition to its role in migration and chemotaxis, LSP1 functions as a positive regulator 
of B cell antigen receptor (BCR) induced apoptosis. Upon stimulation with IgM, LSP1 co-
localizes with membrane IgM in B cells. Treatment of B cells with anti-immunoglobulin 
antibodies imitates the high affinity binding of cross-linking antigens to the BCR, which leads to 
arrest of growth in late G1 phase of the cell cycle and apoptosis. To demonstrate a role for LSP1 
in BCR mediated apoptosis, normal immature B cells were isolated from LSP1 knockout mice as 
well as WT mice and treated with lipopolysacchride, which results in cells enriched for an 
 23 
IgMhigh IgDlow phenotype. These cells were treated with anti-immunoglobulin antibody to induce 
apoptosis. Loss of LSP1 expression lead to decreased anti-IgM induced apoptosis in comparison 
to wild type cells demonstrating that LSP1 is a pro-apoptotic protein in B cells (89). 
Additionally, expression of the C-terminal region of LSP1 (B-LSP1) in the LSP1 positive W10 B 
cell line leads to increased anti-IgM induced apoptosis because B-LSP1 inhibits translocation of 
PKCβI to the plasma membrane. This causes inhibition of ERK2 (extracellular signal regulating 
kinase) activation, which contributes to increased anti-IgM induced apoptosis (90). Therefore, in 
addition to its role as a negative regulator of cellular motility, LSP1 also functions as a positive 
regulator of apoptosis in B cells. 
In resting endothelial cells, LSP1 is predominantly expressed in the nucleus with lower 
levels of LSP1 co-localizing with the F-actin microfilaments. However, upon activation of the 
endothelium, LSP1 interacts with the F-actin cytoskeleton (91). In a LSP1 knockout mouse 
model, loss of LSP1 resulted in decreased permeability in the microvasculature in response to 
histamine (92). Utilizing a chimeric LSP1 -/- model in which the endothelial cells lacked LSP1 
expression and the leukocytes were wild type, neutrophil extravasation was inhibited in response 
to tumor necrosis factor α (TNFα) injection into the cremaster muscle (92). Endothelial LSP1 
plays a role in the formation of endothelial domes, which are crucial for neutrophil 
transendothelial extravasation, in response to the neutrophil chemokine keratinocyte-derived 
chemokine (KC) (91). The ability of leukocytes to adhere to endothelial cells is also facilitated 
by endothelial LSP1.  The adhesion of leukocytes to ICAM-1 expressed on the endothelium 
leads to phosphorlyation and activation of LSP1 through the activation of p38 MAPK (93). LSP1 
expressed in both endothelial cells and leukocytes facilitates the migration and extravasation of 
leukocytes to sites of inflammation.  
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1.4.3 Role in wound healing and fibrosis 
Wound healing is a highly intricate process facilitated by a variety of cell types, growth factors, 
chemokines, and the extracellular matrix. Skin wound healing involves several stages, which 
include inflammation, cellular proliferation and migration, angiogenesis and formation of 
extracellular matrix (94).  In the inflammation phase, neutrophils and macrophages are recruited 
to the site of injury.  During the proliferation stage, tissue granulation and re-epithelialization 
occurs due to the migration and proliferation of keratinocytes, endothelial cells and fibroblasts. 
Finally in the remodeling stage of wound healing, proteolytic enzymes degrade excess collagen 
in the wound, which completes repair of the skin (94, 95).  
Since LSP1 is expressed in leukocytes, which play an important role in inflammation and 
wound healing, the role of LSP1 in skin wound healing was assessed. Using a global LSP1 
knockout mouse model, loss of LSP1 expression led to accelerated full thickness skin wound 
healing in comparison to wild type controls. There was a significant increase in the number of 
neutrophils, macrophages and fibrocytes recruited during the inflammatory stage to the wound in 
the LSP1 null mice. Re-epithelialization, synthesis of collagen, and angiogenesis were also 
enhanced in the LSP1 knockout mice, which correlates with the increase in inflammatory cells in 
the wound. Additionally, expression of macrophage derived chemokines, macrophage 
inflammatory proteins MIP-1α and MIP-2 as well as monocyte chemoattractant protein-1 (MCP-
1) and growth factors, vascular endothelial growth factor (VEGF) and transforming growth 
factor-βI (TGF βI) were increased in the LSP1 null mice in comparison to wild type mice.  
Therefore, loss of LSP1 expression leads to increased skin wound healing due to the increased 
recruitment of leukocytes to the site of injury, which leads to elevated expression of chemokines 
and growth factors that promote healing (95). 
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The function of LSP1 in skin fibrosis was studied since inflammation plays a key role in 
both wound healing and fibrosis. During tissue repair, an inflammatory response occurs in which 
cytokines are produced and released from leukocytes at the site of injury.  This stimulates 
fibroblast to become activated and proliferate.  When this process becomes unregulated, the 
result is fibrosis, in which myofibroblasts secrete extracellular matrix (ECM) proteins and pro-
inflammatory cytokines at the site of injury. The myofibroblasts are derived from resident 
fibroblasts, which are stimulated by pro-fibrotic growth factors, such as TGF-β. To determine the 
role of LSP1 in skin fibrosis, LSP1 null mice were injected subcutaneously with bleomycin, 
which produces a dermal lesion similar to scleroderma. Lack of LSP1 expression led to a 
significant increase in skin fibrosis with increased recruitment of neutrophils, macrophages and 
fibrocytes as well as enhanced collagen synthesis and upregulation of growth factor and 
chemokine expression (96). Therefore, the function of LSP1 in the process of skin fibrosis is to 
regulate leukocyte recruitment to the site of injury leading to increased growth factor and 
chemokine production. 
1.4.4 LSP1 related signaling pathways 
In human neutrophils, MAPKAPkinase 2 (MK2), a target of p38 MAPK, phosphorylates LSP1 
after treatment with fMLP, a chemotactic protein (97, 98). Inhibition of p38 MAPK activation in 
neutrophils leads to inhibition of both LSP1 and MK2 phosphorylation demonstrating that p38 
MAPK is upstream of LSP1 and MK2 activation (99).Additionally, use of the PI3kinase (PI3K) 
inhibitor wortmannin leads to inhibition of p38 MAPK, MK2 and LSP1 activation revealing that 
PI3K is upstream of p38 MAPK in this pathway (98). In neutrophils, PI3K regulates the 
activation of p38MAPK, which phosphorylates MK2 followed by MK2 phosphorylating LSP1.  
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Additional evidence to demonstrate the role MK2 plays in LSP1 phosphorylation is that 
MK2 -/- mice display a similar phenotype to LSP1 -/- mice. In vitro, MK2 -/- neutrophils 
induced by fMLP exhibited increased migration on fibrinogen, which recognizes the integrin 
Mac-1. In response to fMLP in vivo, loss of MK2 lead to increased migration of neutrophils into 
the peritoneum in comparison to wild type (100, 101).  Therefore, LSP1 negatively regulates 
neutrophil migration and chemotaxis through its phosphorylation by MK2.   
LSP1 is a target of protein kinase C (PKC) because treatment of cells with the phorbol 
ester, PMA, as well as diacylglycerol, which activates PKC, leads to increased phosphorylation 
of LSP1. However, in neutrophils treated with fMLP, Bim1, a PKC inhibitor, was not able to 
block phosphorylation of LSP1 indicating that PKC likely functions in regulating the 
p38MAPK/MK2 pathway induced by fMLP in these cells (98). Previous studies have 
demonstrated that LSP1 interacts with PKCβI, which is required for activation of ERK2, but not 
PKCα or βII. PKCβI activation of ERK2 acts to prevent anti-IgM induced apoptosis in B 
lymphoma cells (90). LSP1 and PKCβI interact in a larger signaling complex, which contains 
kinase suppressor of Ras (KSR), an ERK scaffold protein, ERK2 and MEK1, which activates 
ERK. The role of LSP1 is to target this KSR/ERK complex to the actin cytoskeleton. Expression 
of a truncated LSP1, which contains the c-terminal region of the protein, blocks translocation of 
PKCβI to the plasma membrane and activation of ERK2 in response to anti-IgM leading to 
increased apoptosis. Treatment of a B-lymphoma cell line with anti-IgM leads to activation of 
LSP1 associated MEK1 but this MEK1 activation is inhibited when the truncated LSP1 is 
expressed. This suggests that activation of MEK1 associated with LSP1 is dependent on PKCβI 
activation (102). Therefore, in response to anti-IgM, LSP1 functions to target PKCβI, KSR, 
MEK1 and ERK2 to the actin cytoskeleton facilitating PKCβI activation of the ERK pathway.  
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The ERK/MAPkinase signaling pathway functions to transmit signals from extracellular 
stimuli at the plasma membrane to numerous downstream targets in both the nucleus and 
cytoplasm to induce a variety of cellular processes such as proliferation, migration and 
differentiation among others. ERK signaling is able to elicit cellular responses to different 
external stimuli through its targeting to the correct intracellular location. Activated ERK can 
translocate to the nucleus to phosphorylate transcription factors while a different group of ERK 
can phosphorylate cytoplasmic substrates (103).  The MAP kinases ERK1 and ERK2 are 
activated and phosphorylated by the ERK/MAP kinase kinases (MAPK), MEK1 and MEK2, 
which are activated through phosphorlyation by the MAP kinase kinase kinases (MAPKKKs) 
such as Raf. The ERK/MAPK pathway is activated by Ras and PKC through Raf-1 (104).  
A scaffold protein that ensures ERK is targeted to the proper intracellular location is 
kinase suppressor of Ras (KSR), which binds directly to ERK and its upstream activator, MEK 
as well as LSP1 (105-108). KSR was identified in genetic screens of Drosophila and C. elegans 
for Ras related genes. KSR shares the most similarity with Raf kinases, however KSR and Ras 
differ in three major ways: first, KSR does not contain Ras binding domains; second, the N 
terminus contains a unique conserved region of ~40 amino acids, called Conserved Area 1 
(CA1); and lastly instead of containing a lysine residue in the kinase subdomain II, which is 
critical for the phosphotransfer reaction, KSR has an arginine residue suggesting that KSR lacks 
kinase activity (105). KSR is localized to the cytoplasm in unstimulated cells but upon 
stimulation with growth factors, KSR translocates to the plasma membrane along with MEK and 
ERK (107, 109-111).  
There is some controversy as to the function of KSR.  Some previous studies have 
demonstrated that KSR blocks MEK1 activation, which reduces Ras induced NIH3T3 mouse 
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fibroblast transformation. Overexpression of KSR in chicken embryonic neuroretina (NR) cells 
inhibited Ras and B-raf induced proliferation but was unable to inhibit proliferation induced by 
constitutively active MEK1 indicating that KSR inhibits these cellular processes by blocking 
MEK1 activation (106). However, others have found that KSR, in a Ras dependent manner, acts 
to coordinate a RAF/MEK complex, which promotes phosphorylation of MEK and propagates 
the signal through the ERK/MAPK pathway (105, 112). This discrepancy in the function of KSR 
is thought to be due to the expression level of KSR. If there is excess KSR present in the cell due 
to transfection, this may lead to sequestration of components of the MEK/ERK pathway from 
each other preventing their activation (113). In dendritic cells, LSP1, along with KSR and CNK, 
modulate Raf-1 activation when mannose-expressing pathogens bind to the pattern recognition 
receptor, DC-SIGN (114). The function of KSR in modulating the ERK/MAPK pathway is 
controversial and appears to depend mainly on the level of KSR expression and the cell type 
involved. 
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2.0  LEUKOCYTE SPECIFIC PROTEIN-1 EXPRESSION IN HEPATOCYTES, 
DURING LIVER REGENERATION AND IN HEPATOCELLULAR CARCINOMA 
CELL LINES 
Portions of Chapter 2 are adapted from: Kelly Koral, Shirish Paranjpe, William C. 
Bowen, Wendy Mars, Jianhua Luo, and George K. Michalopoulos. Leukocyte specific 
protein-1: a novel regulator of hepatocellular proliferation and migration deleted in human 
hepatocellular carcinoma. Hepatology. 2015 Feb 6;61(2):537-47.  
 
2.1 INTRODUCTION 
Hepatocellular carcinoma (HCC), the most common form of liver cancer, is characterized by 
high rates of mortality. The 5-year survival rate of individuals with HCC is relatively low at 
approximately 15%, which stems in part from the lack of effective treatment modalities. HCC is 
often resistant to current anticancer therapies and underlying diseases of the liver, such as 
cirrhosis, can limit the use of chemotherapeutic agents leading to increased lethality of HCC. An 
effective therapeutic alternative is surgical tumor resection; however this can only be 
implemented in patients with localized disease and liver transplant can only be performed in 
patients that meet strict criteria (44). Since there is only a basic understanding of the molecular, 
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cellular and environmental processes that lead to this disease and limited treatment options, 
additional studies must be conducted to gain a better understanding of the development and 
progression of HCC in order to develop novel therapeutic modalities to combat this lethal 
disease.  
 
In a previous publication from our laboratory, copy number variation (CNV) analysis was 
performed on 98 human HCC samples. The results revealed a portion of the gene for leukocyte-
specific protein (LSP1), an intracellular F-actin binding protein expressed in neutrophils, 
macrophages and endothelial cells, is deleted or amplified (in its carboxy-terminal F-actin 
binding site) in a majority of HCCs evaluated (51 of 98 cases) (74, 75). All of the deletions and 
amplifications of LSP1 affected the C-terminal F-actin binding region, indicating alteration of 
this portion of the LSP1 gene may play an important role in the development or progression of 
HCC (74). There are no previous reports defining a role for LSP1 in the liver or establishing the 
expression of LSP1 in normal liver cells. Therefore, given the very high frequency of LSP1 CNV 
in human HCC, the expression and function of LSP1 in normal hepatocytes should be fully 
elucidated.  
 
Previous studies have demonstrated that mice deficient in LSP1 display accelerated skin 
wound healing and that LSP1 functions to negatively regulate migration of neutrophils (95). 
LSP1 acts as a scaffold through KSR for the extracellular signal-regulated kinase/mitogen 
activated protein kinase pathway (ERK/MAPK) and targets proteins of this pathway to the actin 
cytoskeleton (102). Signaling through the ERK/MAPK pathways leads to a variety of cellular 
processes including migration, proliferation, differentiation, and survival and is a key signaling 
pathway in the progression of proliferating hepatocytes through G1 phase of the cell cycle during 
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liver regeneration (115). LSP1 specifically binds to Kinase Suppressor of Ras (KSR), a key 
regulator of cellular growth due to its function as a scaffold for MAPK and Raf kinase (116, 
117). Therefore, loss of LSP1 function may remove suppressing effects on KSR and 
ERK/MAPK signaling, leading to aberrant hepatocyte proliferation and facilitation of HCC 
development. In the present study, we demonstrate that LSP1 is expressed in cultured 
hepatocytes and after the termination of proliferation. Further, the rat hepatoma cell line JM1 
expresses LSP1 protein, which, through co-immunoprecipitation analysis, interacts with KSR 
and F-actin in these cells.  Loss of LSP1 expression in the hepatoma cell line leads to increased 
migration and proliferation, suggesting that LSP1 acts as a negative regulator for these processes. 
Expression of LSP1 by suitable expression vectors both in vitro (JM2 rat hepatoma cell line) 
leads to decreased proliferation. Therefore, loss of LSP1 expression and function could promote 
HCC development and metastasis (118). 
2.2 EXPERIMENTAL METHODS 
2.2.1 Reagents and Antibodies 
Rabbit anti-LSP1 primary antibody was a generous gift from Dr. Jan Jongstra (University Health 
Network, Toronto, CA). Additional antibodies that were utilized for western blotting, 
immunofluoresence, immunohistochemistry and immunoprecipitation include cyclin D1 
(Neomarkers), phospho-LSP1 (S252) (Abcam), F-actin (Abcam) KSR (Santa-Cruz), 
phophoERK1/2 (tyr202/204) (Cell Signaling Technologies), and total ERK1/2 (Cell Signaling 
Technologies), HNF4α (Santa Cruz), Proliferating cell nuclear antigen (PCNA) (Santa Cruz), 
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Ki67 (ThermoFisher), FITC-phalloidin (ThermoFisher) and β-actin (Sigma). GFP tagged rat 
LSP1 shRNA plasmid and control scrambled shRNA GFP plasmid were purchased from Origene 
(#TG702934). Rat LSP1 cDNA plasmid was purchased from Open Biosystems Dharmacon 
(#MRN1768-202784006) GenJet In Vitro DNA Transfection Reagent (Ver. II) was purchased 
from SignaGen Laboratories for transfection studies.  
2.2.2 Rat hepatocyte isolation and cell culture 
Rat hepatocytes were isolated from normal male Fisher 344 rats using an adaptation of Seglen’s 
calcium two-step collagenase perfusion technique described previously (119, 120). Isolated rat 
hepatocytes (300,000 cells/ml) were cultured on collagen-coated six well plates in hepatocyte 
growth medium supplemented with HGF (40ng/ml) and EGF (20ng/ml) (36, 121). Hepatocyte 
and NPC pellet were harvested along with hepatocytes cultured for 1, 3, 6, 8 and 10 days for 
protein and RNA analysis. Protein samples were collected in RIPA buffer and RNA samples 
were prepared using Trizol reagent (ThermoFisher). 
2.2.3 Two-thirds partial hepatectomy of rat liver and isolation of rat hepatocytes after 2/3 
partial hepatectomy 
Male Fisher 344 rats were subjected to 2/3 partial hepatectomy as previously described 
(11, 121). Briefly, rats were anesthetized using Nembutal (50mg/kg). Rats (n=3 for each time 
point) were sacrificed on days 1, 2, 3, 5, 7 and 10. Regenerating liver tissue was harvested at the 
various time points and either snap frozen for protein and RNA analysis, fixed in 10% formalin 
for paraffin embedding, and embedded into OCT media and frozen at -80°C for cryosectioning. 
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At various time points after PHx, livers were perfused using an adaptation of Seglen’s calcium 
two-step collagenase perfusion techniques as previously described (119, 120). Hepatocyte and 
NPC pellets were collected for protein and RNA analysis on days 1, 2, 3, 5, and 7 after partial 
hepatectomy. 
2.2.4 JM1 and JM2 rat hepatoma cell culture 
JM1 and JM2 rat hepatoma cell lines (122) were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Atlas) and gentamicin 
(1:1000) and maintained in an incubator at 37°C with 5% CO2. 
2.2.5 Immunofluorescence and confocal microscopy 
Frozen rat and mouse liver tissue after PHx were cut into 5-micron thick sections and fixed to 
glass slides. Tissue was fixed in 5% paraformaldehyde for 5 minutes and washed with PBS. 
Sections were blocked in 2% bovine serum albumin (BSA) for 45 minutes, washed in 0.5% BSA 
and incubated in primary antibody (αLSP1 1:50) in 0.5% BSA for 1 hour. Following primary 
antibody incubation, the tissue was washed in BSA and Cy3 conjugated secondary antibody 
(1:1000) along with FITC-phalloidin (1:500) was added to the sections for 1 hour. Hoechst dye 
was used to stain the nuclei and gelvatol was used to fix the glass coverslips to the tissue. Slides 
were stored at 4°C and images were taken at the Center for Biologic Imaging at the University of 
Pittsburgh using an Olympus Fluoview II inverted confocal microscope at both high and low 
power oil immersion objectives for the rat liver tissue. The mouse liver tissue was co-stained 
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with LSP1 (1:50) and HNF4α (1:50 (Santa Cruz)) and imaged using Olympus Provis inverted 
epi-fluorescence microscope in the Center for Biologic Imaging at the University of Pittsburgh.  
2.2.6 Cytoskeleton enrichment of JM1 rat hepatoma cells 
JM1 cells were grown on collagen coated glass coverslips under normal growth medium 
conditions (DMEM +10% FBS+ gentamicin). After 48 hours in culture, the cells were washed in 
a stock solution of 100mM PIPES, pH6.9, 0.1mM EDTA, 0.5mM MgCl2, and 4M glycerol. 
Following the wash, the cytoskeleton was enriched using an extraction buffer which contained 
the stock solution with 0.75% Triton X-100 for 5 minutes at 37°C. After the extraction, the cells 
were washed and then fixed with fixation buffer (stock solution with 2% paraformaldehyde and 
0.01% glutaraldehyde) for 1 hour. The coverslips were stored in PBS at 4°C until they were 
utilized for immunofluorescence. All solutions (wash, extraction, and fixation buffers) were kept 
at 37°C. 
2.2.7 Immunohistochemistry 
Paraffin embedded liver tissue was sectioned into 5μm sections and stained with Ki67 
proliferation marker (ThermoFisher) using the avidin-biotin-peroxidase complex technique 
(Vectastain ABC kit and DAB peroxidase substrate kit, Vector Laboratories). The sections were 
counterstained with hematoxylin. The stained tissue sections were imaged using Olympus Provis 
inverted microscope at 200x magnification. The percentage of Ki67 positive hepatocytes was 
quantified using ImageJ software in at least 10 random fields per tissue section. 
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2.2.8 Immunoprecipitation 
Five hundred micrograms of whole cell lysates from JM1 cells were prepared in RIPA buffer and 
diluted to a final volume of 500μl. Protein complexes were immunoprecipitated with 10μg of 
LSP1 (Santa Cruz), F-actin (Abcam), and KSR (Santa Cruz) antibodies overnight at 4°C with 
end-over-end mixing followed by incubation with protein A/G beads (Santa Cruz) overnight at 
4°C. Complexes were centrifuged at 1,000xg for 5 minutes and washed three times in RIPA 
buffer before resuspension in 2x loading buffer and boiled at 95°C for 15 minutes. 
Immunoprecipitated protein complexes were separated by SDS-PAGE electrophoresis and 
transferred to Immobilon-P PVDF membranes (Millipore). Blots were probed with antibodies for 
total LSP1 using rabbit polyclonal serum (generous gift from Dr. Jan Jongstra), kinase 
suppressor of Ras (KSR) (Santa Cruz Biotechnology) and F-actin (Abcam). The membranes 
were processed with SuperSignal West Pico chemiluminescence substrate (Pierce, Rockford, IL) 
and exposed to X-ray film (Lab Product Sales, Rochester, NY).  
2.2.9 Reverse Transcription and Polymerase Chain Reaction (PCR) 
RNA was obtained by homogenizing rat livers, hepatocytes and cell lines in Trizol ® reagent 
(Invitrogen). RNA was DNase treated using the DNase free Kit from Ambion in order to remove 
any contaminating genomic DNA. Two micrograms of total DNase treated RNA from each 
sample was reverse transcribed into cDNA using Superscript reverse transcriptase (Invitrogen). 
PCR using primers specific for LSP1 (primers) and GAPDH (primers) was performed using Taq 
polymerase (Invitrogen) on a Thermo Hybaid PCR sprint thermal cycler (Thermo Scientific).  
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2.2.10 SDS PAGE and Western blot 
Whole cell protein lysates of liver tissue and cells were prepared using 1% sodium dodecyl 
sulfate (SDS) in RIPA buffer (10mM Na2HPO4, 10 mM NaH2PO4, 150 mM NaCl, 1% NP-40, 
protease inhibitor cocktail (P8340, Sigma), phosphatase inhibitor cocktail I and II (P2850 and 
P5726, Sigma), 0.26 mg/ml amiloride and 0.05 mg/ml AEBSF) and homogenized. Protein 
concentrations were determined using Bicinchoninic acid (BCA) assay (Pierce Chemical Co., 
Rockford, IL) and 30μg protein was loaded and separated on 10% SDS polyacrylamide gels and 
transferred to Immobilon-P membranes (Millipore, Bedford, MA). Following transfer, 
membranes were stained with Ponceau S to evaluate efficient loading and transfer of proteins. 
Blots were probed for 1 hour with primary and horseradish peroxidase (HRP) conjugated 
secondary antibodies separately in Tris-buffered saline (TBS) with Tween 20 containing 5% fish 
gelatin (Sigma, St. Louis, MO). The membranes were processed with SuperSignal West Pico 
chemiluminescence substrate (Pierce, Rockford, IL) and exposed to X-ray film (Lab Product 
Sales, Rochester, NY).  
2.2.11 Statistical Analysis 
All statistical analyses and graphs were prepared on Excel software (Microsoft) utilizing the 
student t-test. Statistical significance was fixed to p values less than 0.05. Error bars on graphs 
represent +/- standard error of the mean (SEM). Densitometry of western blot images was 
analyzed using the National Institute’s of Health ImageJ 4 software and protein loading was 
normalized to either the corresponding Ponceau S staining or β-actin western blots. 
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2.2.12 Approval of Animal Use 
All procedures performed on mice and rats were approved under University of Pittsburgh 
Institutional Animal Care and Use Committee (IACUC) protocols and conducted in accordance 
with the National Institute of Health animal care and use guidelines. 
 
2.3 RESULTS 
2.3.1 LSP1 is expressed in primary hepatocytes in culture 
We demonstrate that LSP1 is expressed in primary rat hepatocytes in culture (Figure 5A and B). 
Expression of LSP1 protein is not seen in the hepatocyte pellet after isolation by collagenase 
perfusion or on day 1 in culture but begins to be expressed starting on day 3 in culture and 
expression steadily increases to day 10 in culture (Figure 5A and B).  The peak of hepatocyte 
proliferation occurs between days 2 and 4 in culture with growth factors HGF and EGF and after 
day 4 in culture proliferation starts to decrease (Figure 6) (36). The correlation between LSP1 
expression and decreased proliferation rates suggests that LSP1 is functioning at the termination 
stage of hepatocyte proliferation in culture. Utilizing RT-PCR we analyzed expression of the two 
LSP1 isoforms in primary rat hepatocytes in culture revealing that in the primary rat hepatocytes 
only isoform 1 is expressed while in the rat hepatoma cell lines both isoforms are expressed 
(Figure 7). 
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Figure 5. LSP1 expression in primary rat hepatocytes in culture, rat liver and hepatocytes after PHx. 
Primary rat hepatocytes were cultured in the presence of HGF and EGF and harvested for A. mRNA 
expression using semi-quantitative RT-PCR (upper panel, LSP1 and bottom panel GAPDH as loading 
control), and B. protein expression by western blot (upper panel, total LSP1, bottom panel, Ponceau S stain, 
loading control).PL: Hepatocyte Pellet; NPC: Non-parenchymal cell fraction; RS: Rat spleen, used as positive 
control.   Whole rat liver was harvested after PHx and LSP1 expression was analyzed using C. RT-PCR (upper 
panel, LSP1, bottom panel GAPDH) and D. western blot of LSP1 (upper panel) and Ponceau S (bottom panel, 
loading control). NL: Normal whole liver lysate; RS: Rat spleen. Rat hepatocytes were isolated from liver 
after PHx by collagenase perfusion and analyzed by E. western blot for total LSP1 (upper panel), 
phophoLSP1 (S252) (3rd panel down) and KSR (4th panel down). F. Quantification of phosphoLSP1 to total 
LSP1 in the rat hepatocytes after PHx. 
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Figure 6. Quantification of BrdU labeling in primary rat hepatocytes in culture. 
Primary rat hepatocytes were pulsed with 2μl of concentrated BrdU solution in 1ml of 
complete growth media supplemented with HGF and EGF. Every two days, cells were fixed in 
10% formalin and stained with BrdU antibody. Percentage of BrdU positive hepatocytes were 
quantified by counting cells in at least three random fields per well. 
Figure 7. RT-PCR of rat hepatocytes in culture and rat hepatoma cell lines for LSP1 
isoforms. Primers were designed for the two most common isoforms of LSP1. Top panel: 
Isoform 1. Bottom panel: Isoform 2. 
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2.3.2 LSP1 expression in liver regeneration 
Next, we analyzed the expression of LSP1 during liver regeneration using the commonly utilized 
2/3 partial hepatectomy (PHx) model (7, 12). LSP1 mRNA and protein expression was observed 
at low levels in whole lysates from normal resting liver and 1 day after PHx (Figure 5C and D), 
which corresponds to the peak of hepatocyte proliferation after PHx in the rat (7, 12). Increased 
LSP1 expression is observed by western blot and immunofluorescence on days 2 and 5 after PHx 
(Figure 5D and 8). Day 2 after PHx, hepatocyte proliferation in the rat is decreased (7, 12) and 
this corresponds with the increased LSP1 expression, which suggests that LSP1 may play a role 
in the termination of proliferation in vivo during regeneration. Since LSP1 expression was 
measured in whole liver after PHx, we are unable to determine which specific cell types of the 
liver are contributing to the signal. This is because LSP1 is heavily expressed in the non-
parenchymal hepatic cell populations (see NPC in Fig. 5B).  Therefore, we isolated rat 
hepatocytes from PHx livers by collagenase perfusion at various time points after PHx and 
measured LSP1 expression. Western blot analysis for total LSP1 revealed that LSP1 is expressed 
at low levels at time 0 but steadily increases until day 7 (Figure 5E). The percentage of 
hepatocytes in comparison to NPCs after perfusion was not determined therefore it is possible 
that some of the LSP1 expression detected is due to the presence of NPCs. Analysis of phopho-
LSP1 levels indicates a peak of expression at day 2 after PHx in the hepatocytes (Figure 5E and 
F). Upon phosphorylation of LSP1 at serine 252, LSP1 localizes to the F-actin filaments (75) 
which corresponds to the co-localization of F-actin and LSP1 observed in rat liver after PHx 
(Figure 8 and 9). Western blot analysis of total LSP1 in isolated NPCs after PHx showed a 
marked increase in expression on day 3 after PHx (Figure 10).  
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Figure 8. Immunofluoresence of LSP1 and F-actin in rat liver after PHx. Rat liver was 
harvested at various time points after PHx and was probed for LSP1 and F-actin. First panel is 
DAPI to stain the nuclei, second panel shows the F-actin signal, third panel shows the signal for 
total LSP1 and the last panel displays a merge of the DAPI, F-actin, and total LSP1 signals. 600x 
magnification. Scale bar =50μm 
 
. 
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Since LSP1 is an F-actin binding protein in hematopoietic cells, we utilized 
immunofluorescence to determine if LSP1 and F-actin co-localize in hepatocytes during liver 
regeneration. LSP1 and F-actin do co-localize at day 2 after PHx as indicated by the yellow 
signal observed in the merged images and this co-localization appears to be hepatocellular, since 
the size, shape and morphological characteristics of the LSP1 positive cells is consistent with 
hepatocytes (Figure 8 and 9).  It is possible that the LSP1 expression observed is due to cells 
surrounding the hepatocytes such as stellate cells. This possibility could be tested by performing 
IF with stellate cell markers such as GFAP or desmin along with LSP1 staining and measuring 
co-localization. Strong expression of LSP1 in the vascular endothelium and portal mesenchyme 
(Figure 8) is expected since previous literature has demonstrated LSP1 expression in endothelial 
and mesenchymal cells (79, 92).  
LSP1 has been shown to interact with Kinase Suppressor of Ras (KSR), an ERK/MAPK 
pathway scaffold, and target these proteins to the actin cytoskeleton (102). Therefore, we also 
measured the expression of KSR in the isolated rat hepatocytes after PHx. KSR expression is 
observed in normal resting hepatocytes and it slightly increases towards the end of regeneration 
(Figure 5E).  
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Figure 9. Quantification of LSP1 and f-actin immunofluoresence co-localization in rat liver 
after partial hepatectomy. Co-localization intensity was quantified from at least three 
independent fields using Metamorph software. Representative IF images are shown in figure 8. 
Figure 10. Total and phospho LSP1 expression in rat non-parenchymal cells (NPC) after 
PHx.  Western blot analysis of total LSP1 expression (top panel) and phosphoLSP1 expression 
(3rd panel) in rat NPC after PHx. Ponceau S stain (loading control). 
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2.3.3 LSP1 expression in hepatoma cell lines and interactions with ERK/MAPK scaffold 
Kinase Suppressor of Ras (KSR) 
Expression of LSP1 was measured in two rat hepatoma cell lines, JM1 and JM2 (122). JM1 and 
JM2 cells exhibit different morphological and functional characteristics. Both JM1 and JM2 cells 
expressed LSP1 mRNA but only JM1 cell line expressed LSP1 protein (Figure 11A and B). 
Immunofluorescence images demonstrate that LSP1 co-localizes with F-actin in the JM1 cell line 
as well (Figure 11D). Since the LSP1 immunofluoresence signal in the cytoplasm of the JM1 
cells is very strong it is possible that the co-localization with F-actin is an artifact. Therefore, we 
isolated the cytoskeleton of the JM1 cells and performed immunofluoresence on these extracts, 
which removes the high LSP1 signal from the cytoplasm. The results demonstrate that LSP1 and 
F-actin cytoskeleton do co-localize in the JM1 rat hepatoma cells (Figure 12). Next, we utilized 
co-immunoprecipitation to determine if LSP1 interacts with KSR and G-actin in the JM1 cell 
line. The results indicate that LSP1 does interact with KSR and KSR interacts with G-actin in 
these cells (Figure 11C). These findings demonstrate that LSP1 is expressed in a rat hepatoma 
cell line and targets the ERK/MAPK scaffold KSR to F-actin filaments.  
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Figure 11. LSP1 expression in rat hepatoma cell lines and analysis of LSP1, KSR and F-
actin interactions.  JM1 and JM2 cells were analyzed for expression of LSP1 A. mRNA by RT-PCR 
and B. protein by western blotting. C. Co-immunoprecipitation analysis on the JM1 cell line for 
interactions between LSP1, KSR and G-actin. Upper panel: IP of LSP1 and western blot of LSP1 
(top) and KSR (bottom). Middle panel: IP of KSR and western blot of LSP1 (top) and KSR 
(bottom). Bottom panel: IP of KSR and western blot of KSR (top) and F-actin (bottom). D. IF 
images of JM1 cells for DAPI (top panel), Phalloidin (2nd panel), LSP1 (3rd panel), and merge 
(bottom panel). Images were taken at 400x magnification. Scale bar = 50μm 
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Figure 12. LSP1 and f-actin immunofluoresence in cytoskeletal extracts of JM1 rat 
hepatoma cells. Phalloidin (green, top left), LSP1 (red, top right), and merge (bottom) 
immunofluoresence images of cytoskeleton that has been extracted from JM1 rat hepatoma 
cells. Scale bar = 100μm. 
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2.4 DISCUSSION 
A previous study from our laboratory demonstrated that in human HCC, LSP1 CNV was found 
in the highest number of cases (74); however the expression and functional role of LSP1 in both 
normal liver and HCC is unknown. The finding arrived as a surprise since there is no literature 
on LSP1 in hepatic biology. In order to place the role of LSP1 in the perspective of normal liver 
biology, and thus get a framework for understanding its role in hepatic neoplasia, we embarked 
upon the studies described above, to provide a baseline of LSP1 functions in normal liver and 
obtain evidence from experimental models as to its functional significance.  As a first step in this 
study, we aimed to determine if LSP1 is expressed in liver, specifically in the hepatocytes, and 
the role LSP1 plays in hepatocyte growth regulation. LSP1 is intensely expressed in endothelial 
cells and cells of hematopoietic origin. Thus, studies of LSP1 in whole liver tissue are not likely 
to be informative since hepatocyte expression of LSP1 is likely to be overwhelmed by the 
intense expression of LSP1 in hepatic macrophages and endothelial cells. Because of this, we 
concentrated our studies in hepatocytes in primary culture or in hepatocytes isolated by 
collagenase perfusion at different stages of regeneration. Our results indicate that LSP1 
expression is not observed in normal hepatocytes until day 3 in culture and expression increases 
over time. Since hepatocytes in culture experience the peak of proliferation between days 2-4 
and the highest level of LSP1 expression is observed on day 10, it is reasonable to conclude that 
LSP1 may be associated with a termination signal for hepatocyte proliferation (36).  Analysis of 
LSP1 expression during liver regeneration demonstrates that the peak of expression occurs on 
day 7 (Fig. 5E) providing further support for the role of LSP1 as associated with inhibition of 
hepatocyte growth (7, 12).  Measurement of phophoLSP1 in regenerating hepatocytes also 
reveals increased expression on day 2 after PHx. Phosphorylation of LSP1 at serine 252 
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corresponds with increased binding to the F-actin filaments, which was detected in both 
hepatocytes (day 2) and NPCs (days 1-3).  
Our findings revealed changes in LSP1 expression and association with its binding 
targets (F-actin filaments) during rat liver regeneration. Immunofluorescence analysis shows that 
LSP1 co-localizes with hepatocyte F-actin on day 2 following PH, which suggests that the ability 
of LSP1 to bind to the actin filaments may be vital for its role in controlling proliferation. In the 
CNV study of HCC, all of the amplifications and deletions of LSP1 affected the C-terminal 
region of the gene, which encodes for the F-actin binding elements of LSP1 (74). We have 
assumed that amplification of the C-terminal portion of LSP1 may create a situation of a 
dominant negative protein containing only the C-terminal, which may interfere with the binding 
of the complete protein. This further supports the role of LSP1 in terminating proliferation and 
that loss of its ability to bind to F-actin by deletion of c-terminal region could lead to aberrant 
hepatocyte cell division, leading to or enhancing carcinogenesis.   
Since LSP1 CNV was discovered in human HCC and our experimental studies were 
carried out in the rat, we measured the expression of LSP1 in two distinct rat hepatoma cell lines, 
JM1 and JM2 (122). JM1 cells expressed LSP1 RNA and protein as demonstrated by RT-PCR, 
western blot and immunofluoresence. To demonstrate how LSP1 functions in these cells, co-
immunoprecipitation and immunofluoresence displayed that LSP1 interacts and co-localizes with 
F-actin and the ERK/MAPK pathway scaffold KSR, respectively. KSR functions by targeting 
MEK1 and ERK2 to the actin cytoskeleton. In unstimulated cells, this complex is mainly 
localized to the cytoplasm. Upon growth factor stimulation, KSR translocates to the plasma 
membrane thereby targeting ERK2 and its direct activator MEK1 to the plasma membrane (102, 
117). KSR functions to both potentiate and attenuate ERK cascade activation thereby regulating 
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the intensity and duration of ERK pathway signaling from the plasma membrane during growth 
factor stimulation. The ERK/MAPkinase pathway transmits signals from the plasma membrane 
to a plethora of cytoplasmic and nuclear targets that affect downstream functions such as 
proliferation, differentiation and survival. Scaffolding proteins, such as LSP1 and KSR, target 
the ERK cascade to the appropriate intracellular location, which ensures the correct response of 
the ERK pathway to various extracellular signals (117). Therefore, in HCC, if LSP1 functions as 
a growth suppressor and there is a loss of LSP1 expression, this could affect the ERK/MAPK 
pathway leading to aberrant proliferation or migration. 
The literature documents the presence of several isoforms for LSP1 in different cell types 
as a result of alternative splicing (123). As shown in Fig. 5D, there are two protein isoforms in 
whole liver homogenates. We also noticed that Fig. 5E demonstrates that hepatocytes express 
only the higher molecular weight isoform. However, only the lower molecular weight mRNA is 
expressed in hepatocytes in Fig. 7. The significance of this is not clear. There are multiple 
isoforms described for LSP1 in the literature (79, 123) and the importance of this should be 
further investigated. 
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3.0  LEUKOCYTE SPECIFIC PROTEIN-1 REGULATES HEPATOCELLULAR 
MIGRATION AND PROLIFERATION IN VITRO AND IN VIVO 
Portions of Chapter 3 are adapted from: Kelly Koral, Shirish Paranjpe, William C. Bowen, 
Wendy Mars, Jianhua Luo, and George K. Michalopoulos. Leukocyte specific protein-1: a 
novel regulator of hepatocellular proliferation and migration deleted in human 
hepatocellular carcinoma. Hepatology. 2015 Feb 6;61(2):537-47. 
3.1 INTRODUCTION 
In chapter 2, we demonstrated that LSP1 is expressed in primary hepatocyte cultures as well as 
during liver regeneration after partial hepatectomy. Our results also showed a role for LSP1 in 
the migration and proliferation of hepatoma cell lines in vitro. In chapter 3, we will explore the 
role of LSP1 in vivo during liver regeneration and provide evidence demonstrating that 
expression of LSP1, either through hydrodynamic tail vein injection of plasmid DNA or in a 
transgenic mouse model, will significantly decrease proliferation and ERK activation after partial 
hepatectomy and, loss of LSP1 expression will cause an increase in ERK phosphorylation as 
well as hepatocellular proliferation during regeneration.  Perfusion of both knockout and 
transgenic LSP1 mouse livers and culture of hepatocytes will further validate the role of LSP1 in 
hepatocellular proliferation as well as migration.  
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3.2 EXPERIMENTAL METHODS 
3.2.1 Transfection of JM1 cells and creation of stable cell lines 
JM1 cells were transfected with either GFP-LSP1 shRNA plasmid (Origene, #TG702934) or 
scrambled shRNA plasmid (Origene) for a control at ~85% confluency in 6 well plates using 
lipofectamine 2000 (Invitrogen).  Briefly, following the manufacturer’s protocol, the cells were 
transfected with 4μg of plasmid DNA in serum free DMEM overnight. Serum free media was 
replaced with DMEM containing 10% FBS and 72 hours post transfection, the cells were 
trypsinized and plated in a 10mm dish and treated with 10μg/ml puromycin (Sigma) for the 
selection of stably transfected cells. Stable clones were screened for the expression of GFP by 
fluorescence microscopy and only clones expressing GFP were isolated and maintained in the 
presence of 10μg/ml puromycin.  
JM2 cells were transiently transfected with either pExpress-1 vector alone (control) or rat 
LSP1 cDNA (Dharmacon #MRN1768-202784006) using GenJet In Vitro DNA Transfection 
Reagent (Ver. II) (SignaGen Laboratories) at 80% confluency in 6 well plates. The cells were 
transfected with 4μg of plasmid DNA complexed with 8ul of transfection reagent in DMEM 
supplemented with 10% FBS. Cells were incubated with transfection complexes for 8 hours 
before the medium was changed and further experimental procedures were performed including 
BrdU assay and protein isolation at 24 hours post transfection.  
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3.2.2 MTT and Bromodeoxyuridine (BrdU) assays 
For the MTT assay, JM1 stable cells (LSP1 shRNA and scrambled control cell lines) were plated 
at 1x105 cells/well in 2- 6 well plates and cultured in DMEM + 10% serum. At approximately 
50% confluency, the media in both plates was changed to serum free media. Baseline MTT 
values were measured at 24 hours after addition of serum free medium. Proliferation was 
stimulated with 10% FBS in DMEM and absorbance measured after 24 h. MTT absorbance after 
24 h was normalized to the baseline measurements. 
For BrdU assay, transiently transfected JM2 cells were treated with 2μl of 
bromodeoxyuridine (BrdU) 8 hours after transfection in DMEM with 10% FBS. At 24 hours post 
transfection, the cells were fixed in 10% formalin and stained using an antibody against BrdU 
(Invitrogen) using standard immunohistochemical techniques. Images were taken of the stained 
cells using Provis Fluoview Microscope and quantified using Image J software.  
3.2.3 Scratch and Transwell migration assays 
For the scratch assay, cells were plated at 2x105 cells/well in a 6 well plate and cultured in 
DMEM + 10% FBS until confluent. Upon confluency, a scratch was made in the monolayer 
using a 10μl pipette tip and the cells were washed in DMEM to remove unattached cells. An 
image was taken using an inverted fluorescence microscope at the time of the scratch (time 0) 
and 24 hours post scratch. Live cell imaging was also performed on the scratch assay cultures. At 
the time of the scratch, the 6 well plate was placed in the incubation chamber of the live cell-
imaging microscope and images were taken of each scratch every 2 hours for 24 hours.  
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For the transwell assay, cells were seeded at 1x105 cells per transwell insert in serum free 
medium. The bottom chamber of the well contained DMEM with 10% serum. Cells were 
allowed to migrate for 24 hours at 37°C. After 24 hours, the cells that migrated to the bottom of 
the transwell membrane were fixed in 4% paraformaldehyde and stained with a 0.1% Coomassie 
blue/ 10% methanol/ 10% acetic acid solution. Cells that did not migrate through the membrane 
were carefully removed using a cotton tipped applicator. The membranes were imaged using an 
Olympus Provis inverted microscope and the cells of at least three fields per membrane were 
counted using Image J software. 
3.2.4 Hydrodynamic injection of LSP1 plasmid DNA and 2/3 PHx 
Male FVB mice (4 month old) were subjected to a hydrodynamic tail vein injection of either 
pExpress-1 control plasmid (n=5) or rat LSP1 cDNA plasmid (n=3) (Open Biosystems 
Dharmacon). Briefly, 20 μg of endotoxin free plasmid DNA was diluted in 2ml of 0.9% sterile 
endotoxin free saline solution. The DNA/ saline solution was injected through the tail vein in 7 
seconds. Following a three-hour recovery period, the mice were subjected to a 2/3 partial 
hepatectomy, as previously described (43). The livers were harvested 42 hours post hepatectomy 
and the tissue was processed for paraffin embedding, frozen OCT embedding and protein 
isolation.  All procedures performed on mice and rats were approved under IACUC protocols 
and conducted in accordance with the National Institute of Health animal care and use 
guidelines. 
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3.2.5 LSP1 knockout mouse model 
LSP1 global knockout mice were created by Dr. Jenny Jongstra-Bilen on a 129/SvJ background 
as previously described (81) and were obtained from Dr. Lixin Liu from the University of 
Saskatchewan. Since the mouse LSP1 gene encodes 2 different tissue specific isoforms, LSP1 
and S37, with the only difference between the two isoforms being a unique amino terminus due 
to alternative splicing, only the LSP1 specific exon 1 was targeted to prevent embryonic lethality 
due to the importance of S37 in mouse development. Therefore, the LSP1 isoform is absent in all 
tissues of these mice leaving the S37 expression intact globally (81).The LSP1 KO mice along 
with the 129/SvJ WT mice were utilized for PHx studies as well as hepatocyte cultures.   
3.2.6 Creation of hepatocyte specific LSP1 transgenic mouse model 
Hepatocyte specific LSP1 transgenic mice were created in conjunction with Dr. Kyle Orwig at 
the Magee Women’s Research Institute Transgenic and Molecular Research Core Facility on a 
C57/BL6 background. Mouse LSP1 cDNA was cloned into the BamH1 sites of a plasmid 
containing an albumin promoter and alpha-fetoprotein enhancer to ensure expression of LSP1 in 
hepatocytes only since the albumin promoter is only active in the hepatocytes. The transgenic 
mice were created using the pronuclear injection technique in which the LSP1- albumin 
promoter plasmid DNA is injected into donor zygotes, which are implanted into pseudopregnant 
female mice. The offspring were screened for the presence of the transgene using PCR. Mice 
positive for the transgene were mated to control mice in order to determine if the transgene 
inserted into the genome multiple times (124). Once a pure line was established the transgenic 
mice were bred together to create a homozygous transgenic mouse line, which were utilized in 
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the 2/3 partial hepatectomy studies as well as hepatocyte cultures. Expression of LSP1 protein in 
the liver was assessed by western blot.  
3.2.7 Mouse hepatocyte isolation and culturing 
Mouse hepatocytes were isolated from WT C57/Bl6, WT 129/SvJ, LSP1 knockout and 
transgenic mice using an adaptation of Seglen’s calcium two-step collagenase perfusion 
technique described previously (119, 120). Isolated mouse hepatocytes (300,000 cells/ml) were 
cultured on collagen-coated six well plates in MHGM supplemented with HGF (40ng/ml) and 
EGF (20ng/ml) (36, 121, 125). Hepatocyte were treated with BrdU on 0-2, 2-4, 4-6 days and 
fixed with formalin for immunohistochemistry. Protein samples were collected in RIPA buffer 
on days 0 (pellet), 2, 4, and 6. 
 
3.3 RESULTS 
3.3.1 Loss of LSP1 expression using shRNA in vitro leads to increased proliferation and 
migration 
Since LSP1 protein is expressed in the JM1 cell line, we utilized these cells as a model to 
measure the functional significance of the loss of LSP1 in HCC.  We transfected the JM1 cell 
line with short hairpin RNA (shRNA) in order to knock down expression of LSP1 and then 
measured the effect of loss of LSP1 on proliferation and migration.  Since the shRNA vector 
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contained a puromycin resistance gene, we created a stable cell line and first measured the 
expression of LSP1 (Figure 13). Western blot analysis demonstrates a marked decrease in LSP1 
protein expression in the LSP1 shRNA transfected cell in comparison to the scrambled shRNA 
control cells (Figure 14).  
 
 
 
 
Figure 13.  Creation of a LSP1 shRNA expression stable JM1 hepatoma cell line. A. Representative 
brightfield (top) and GFP (bottom images of the stable scrambled (left) and LSP1 shRNA (right) expressing 
JM1 cells. Scale bar = 10μm B. Western blot analysis of total LSP1 expression in the scrambled shRNA 
(scr.) and LSP1 shRNA stable cell lines. Ponceau S was utilized to ensure equal loading. C. Quantification 
of total LSP1 expression in western blots from B. Scale bar = 10μm.  
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Next, using immunoblotting, we measured the expression of the commonly utilized 
proliferation marker, cyclin D1. LSP1 shRNA JM1 cells exhibited increased levels of cyclin D1 
in comparison to scrambled control indicating an increased proliferation in the LSP1 shRNA 
cells (Figure 14A). Next, a MTT assay was performed in which two LSP1 shRNA cell lines 
demonstrated a 3 and 4-fold increase in absorbance in comparison to scrambled controls 
indicating an increase in mitochondrial activity (Figure 14B). Since LSP1 is known to negatively 
regulate migration in leukocytes and endothelial cells (75, 92), we measured migration of LSP1 
shRNA cells using a “monolayer scratch” assay and a transwell migration/chemotaxis assay. 
Loss of LSP1 expression led to increased migration into the scratch with an approximately 50% 
increase in wound closure in the LSP1 shRNA JM1 cells compared to scrambled shRNA cells 
(Figure 14C and D, Figure 15) as well as a four-fold increase in the number of cells that migrated 
across the transwell membrane (Figure 16). To determine the mechanism by which LSP1 
knockdown resulted in increased proliferation and migration, we analyzed expression of 
downstream signaling pathways. Since LSP1 is known to interact with KSR and the MEK/ERK 
pathway signaling proteins, we analyzed expression of phosphorylated ERK2. Loss of LSP1 
expression resulted in increased phosphorylated ERK2 indicating increased ERK2 activation and 
suggesting that the increased proliferation and migration occurs through an ERK activated 
mechanism (Figure 14E and F).  
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Figure 14. Functional analysis of loss of LSP1 expression in JM1 hepatoma cell line. JM1 cells 
were transfected with LSP1 shRNA and a stable cell line was created. A. Western blot analysis of the 
stable LSP1 shRNA JM1 cell line for total LSP1 (top panel), cyclin D1 (2nd and 3rd panel), and β-
actin (bottom panel, loading control).  B. MTT assay of scrambled shRNA control cells and two LSP1 
shRNA stable clones (LSP1 shRNA 1 and LSP1 shRNA 2). n=18 (experiment repeated at least two 
independent times), p=1.99e-06 and p=0.002, respectively.  C.  Representative bright field images of 
migration “scratch” assay at time 0 (upper panels) and 24 hours post scratch (bottom panel). Scale 
bar = 10μm.  D. Quantification of area of wound closure from scratch assay. n=6, p=4.98e-06. E. 
Representative western blot of phophoERK2 (top panel) and total ERK2 (middle panel) in JM1 LSP1 
shRNA stable cell lines. F. Quantification of pERK2 and total ERK2. n=7, p=0.0157. 
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Figure 15. Live cell imaging of migration scratch assay of JM1 LSP1 shRNA stable cell line. 
Left panel: scrambled shRNA stable cell line. Right panel: LSP1 shRNA stable cell line. Images were 
taken every 2 hours for 18 hours. 100x magnification. Scale bar= 100μm. 
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Figure 16. Transwell Migration Assay of JM1 LSP1 shRNA stable cell line. A. 
Representative images of 0.1% Coomassie blue/10% methanol/10% acetic acid stained cells 
that migrated to the bottom of the transwell membrane. Images were taken using Olympus 
Provis inverted microscope at a 100x magnification. Scale bar = 100μm. Left panel: scrambled 
shRNA stable cells. Right panel: LSP1 shRNA JM1 stable cell line. B. Quantification of the number 
of migrating cells. At least 3 random fields per membrane were counted using Image J software 
(NIH). 
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3.3.2 Expression of LSP1 in a LSP1 deficient cell line leads to decreased proliferation 
Loss of LSP1 expression in the JM1 rat hepatoma cell line lead to increased mitochondrial 
activity and cyclin D1 expression therefore next we wanted to demonstrate if expression of LSP1 
in a normally deficient cell line affects proliferation. JM2 rat hepatoma cell line does not express 
LSP1 protein (Figure 11B). Therefore we utilized these cells to study the role of LSP1 
expression on cell proliferation. After transient transfection of JM2 cells with LSP1 cDNA 
(Figure 17A), we observed a significant decrease in the expression of the proliferation marker, 
cyclin D1 (Figure 17B and C). Furthermore, LSP1 expression in these normally deficient cells 
led to an approximate 50% decrease in BrdU labeling indicating a decrease in the rate of 
proliferation (Figure 17D). These results demonstrate that LSP1 functions as an inhibitor of 
hepatoma cell proliferation. We did not measure the role of increased LSP1 expression on 
migration in the JM2 cells however since loss of LSP1 expression leads to increased migration, 
we would hypothesize that increased LSP1 would greatly reduce migration. 
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Figure 17. JM2 cells were transiently transfected with LSP1 cDNA and pExpress-1 plasmid 
(control). A. Western blot analysis of total LSP1 expression (top panel) at 24 hours post transfection in 
transiently transfected JM2 cell line. Ponceau S (bottom panel) loading control. B. Western blot analysis of 
cyclin D1 (top panel) expression at 24 hours post transfection. (Ponceau S (bottom panel), loading 
control). C. Quantification of cyclin D1 protein expression from B. n=3, p=0.002. D. Quantification of BrdU 
labeling in D. n=5 per condition, p=5.93E-05. 
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3.3.3 Expression of LSP1 through hydrodynamic tail vein injection leads to decreased 
proliferation following partial hepatectomy 
To demonstrate a role for LSP1 in the regulation of proliferation in vivo, we performed a 
hydrodynamic tail vein injection of LSP1 cDNA plasmid into male FVB mice and immediately 
performed a 2/3 partial hepatectomy. To show that the livers, specifically the hepatocytes, were 
successfully expressing LSP1 following injection, we performed western blot analysis for LSP1 
expression and immunofluorescence staining of LSP1 and Hepatocyte Nuclear Factor 4α 
(HNF4α), a marker of hepatocytes. The LSP1 injected animals expressed LSP1 and the LSP1 
expression occurred in the cells also expressing HNF4α, demonstrating that a majority of the 
cells expressing LSP1 are hepatocytes (Figure 18A and B). Though there were variations of the 
percentage of hepatocytes with high expression of LSP1 from one lobule to another, on average, 
about 30% of hepatocytes were found to have high LSP1 expression following the hydrodynamic 
injection.  The peak of hepatocyte proliferation after PHx in mice is on day 2 (1). Therefore we 
harvested the livers on day 2 and performed immunohistochemical staining for the proliferation 
marker Ki67. The livers of the LSP1 injected mice displayed approximately 50% less Ki67 
labeled hepatocytes in comparison to the vector control injected mice suggesting that LSP1 plays 
a role in regulating the proliferation of hepatocytes in vivo (Figure 18C and D).  Western blot 
analysis demonstrates that the LSP1 injected mice have decreased cyclin D1 expression as well 
as decreased pERK expression in two out of the three liver samples (Figure 19). The results 
show that enhanced expression of LSP1 at the early (proliferative) stages of liver regeneration 
has inhibitory effects on hepatocyte proliferation. 
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Figure 18. In vivo expression of LSP1 in a mouse PHx model. Hydrodynamic tail vein 
injection was utilized to express LSP1 in vivo during PHx. A. Immunofluoresecence images of 
mouse liver at D2 after PHx (vector control (top panel), and LSP1, (bottom panel)) for HNF4α (left 
panel), LSP1 (middle panel), and merge (right panel). Images were taken at 200x magnification. 
Scale bar =100μm. Inset is shown to demonstrate LSP1 and HNF4α expression is present in the 
hepatocytes. B. Western blot analysis of total LSP1 expression (top panel) and Ponceau S (loading 
control) in total liver lysate from injected mice at Day 0 and 2 after PHx. C. Representative images 
of Ki67 staining of the injected mouse liver tissue on day 2 after PHx. Right image, vector control 
and left image, LSP1 injected animal. All images were taken at 200x magnification. Scale bar = 100 
μm. D. Quantification of the percentage of Ki67 positive hepatocytes in mouse liver tissue on D2 
PHx. At least three random fields per slide were quantified using Image J software.  Vector control 
mice n=5, LSP1 mice n=3. p=1.45E-10. 
Figure 19. Western blot analysis of mouse livers after hydrodynamic tail vein 
injections. Liver samples from vector control and LSP1 injected mice at the time of PHx (time 
0) and on day 2 after PHx were analyzed for expression of LSP1 (top), pERK1/2 (2nd from 
top), total ERK (3rd from top), Cyclin D1 (4th from top), and β-actin (bottom panel). Each lane 
represents one mouse. n=3 per condition. 
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3.3.4 LSP1 KO mice display increased ERK activation and proliferation after partial 
hepatectomy 
Since we have demonstrated that overexpression of LSP1 through hydrodynamic tail vein 
injection of LSP1 plasmid DNA causes decreased proliferation following PHx, next we wanted 
to determine what effect the loss of LSP1 expression would have on proliferation after PHx. We 
hypothesize that the lack of LSP1 expression would result in increased proliferation since LSP1 
acts as an inhibitor of cell growth. Therefore, we performed PHx on a global LSP1 knockout 
(KO) mouse model and using the proliferation marker, Ki67, we measured the percentage of 
proliferating hepatocytes at various times post-surgery. There was no difference in the number of 
Ki67 positive hepatocytes at day 2 following PHx between the WT and KO mice, however on 
day 4, there is a significant increase in the percentage of proliferating hepatocytes in the KO 
mice (25.7%) as compared to the wild type (15.6%) (Figure 20A and B). By day 7, the amount of 
dividing hepatocytes in the KO is significantly less than in the WT mice suggesting that in this 
model, at later time points after PHx, a compensatory mechanism inhibits the increased 
hepatocellular growth. Although the percentage of Ki67 positive hepatocytes is less on day 7 in 
the KO, on both day 4 and 7, there is a significant increase in the number of overall hepatocytes 
in the KO having 144 more hepatocytes on day 4 and 134 more hepatocytes on day 7 than the 
wild type controls (Figure 20C). Despite the increase in Ki67 positive hepatocytes on day 4 and 
increased hepatocyte numbers on days 4 and 7, there was no difference in the liver to body 
weight ratios between the KO and WT mice (Figure 21). 
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Figure 20. LSP1 knockout (KO) mice display increased Ki67 positive hepatocytes on day 4 
after PHx and increased hepatocyte numbers on days 4 and 7. A. Representative images of Ki67 
immunohistochemistry on wild type (WT) (left) and LSP1 KO (right) mouse livers after PHx. 200x 
magnification. Scale bar = 100μm. B. Quantification of the percentage of Ki67 positive hepatocytes 
in WT and LSP1 KO mouse livers after PHx. C. Quantification of the number of hepatocytes per 
200x field in WT and LSP1 KO livers after PHx. ** p<0.001, ***p<0.0001. 
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Figure 21. Liver to body weight ratios of WT and LSP1 KO mice after PHx. Ratio of liver 
weight to body weight was taken on days 2, 4 and 7 after PHx. There is no significant difference 
in the liver to body weight ratio at any of the time points. 
Figure 22. Western blot analysis of LSP1 expression in WT and LSP1 KO mouse livers. 
Total LSP1 expression was measured at time 0 and days 2, 4  and 7 in both the WT and LSP1 KO 
mouse livers. Each lane represents a pooled lysate containing protein from 3 separate mouse 
livers. Ponceau S staining was utilized to ensure equal protein loading. 
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Next, we measured the expression of total LSP1 in the WT and KO mice and western 
blot analysis shows that LSP1 expression is increased in the KO mice (Figure 22), which is most 
likely due to the knockout mice only lacking expression of one isoform of LSP1 leaving 
expression of the S37 isoform of LSP1 intact.  Since the antibody recognizes all LSP1 isoforms, 
S37 is being expressed at a higher level to compensate for loss of isoform 1. This may also 
contribute to the modest difference in proliferation that we measured in the KO after PHx. It is 
possible that one isoform is responsible for effect on proliferation whereas the other isoform S37 
plays a role in migration. Another explanation is that the two different isoforms are differentially 
expressed in hepatocytes and NPCs. We also performed western blot analysis to measure pERK, 
total ERK and cyclin D1 levels in the KO and WT livers following PHx. The KO mice display 
increased pERK levels at all of the time points in comparison to controls however, cyclin D1 
expression is not effected on day 2 and appears to be decreased on days 4 and 7 (Figure 23). This 
conflicts with the increased Ki67 staining on day 4 but could be due to the contribution of the 
other cell types in the lysates since the samples are whole liver lysates and not isolated 
hepatocytes.  
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Figure 23. Western blot analysis of WT and LSP1 KO mouse livers after PHx. A. WT 
and LSP1 KO livers from time 0 (T0) and day 2 (D2), B. time 0 (T0) and day 4 (D4), and C. 
time 0 (T0) and day 7 (D7) were analyzed by western blot for pERK (top), total ERK (2nd 
from top), cyclin D1 (3rd from top) and ponceau S staining (bottom) was utilized to ensure 
equal protein loading. Each lane represents a whole liver lysate from a separate mouse. 
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To determine if the KSR and pERK complex are affected by the loss of LSP1 expression 
during PHx, we performed an immunoprecipitation with KSR and probed for pERK. Overall, 
there is more KSR expressed in the KO as compared to the wild type. In the wild type mice, 
KSR and pERK are in complex on day 2 and day 7 whereas in the KO, KSR and pERK interact 
at all times points except for day 4, which is when we see increased proliferation in the KO as 
compared to the WT (Figure 24). One caveat to this study is that these are whole liver lysates so 
we are unable to determine if the KSR-pERK complex is being formed in the hepatocytes or the 
other cell types of the liver.  
 
 
 
 
 
Figure 24. Immunoprecipitation of KSR in WT and LSP1 KO PHx liver lysates. Top 
panel: western blot for KSR, bottom panel: western blot for pERK expression in WT and LSP1 
KO PHx livers at time 0 and days 2, 4 and 7. 
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3.3.5 Hepatocytes from LSP1 KO mice exhibit increased proliferation in the absence of 
growth factors 
Since it is difficult to determine the effect the loss of LSP1 has on hepatocytes when studying the 
intact liver with the contribution of other cell types, we decided to isolate hepatocytes from the 
WT and KO mice to study the role of LSP1 on their proliferation in culture. We performed BrdU 
incorporation assays on hepatocytes cultured in the presence and absence of HGF and EGF. In 
the presence of growth factors, there was no difference in number of dividing hepatocytes 
between the WT and KO at all of the time points measured (Figure 25). However, in the absence 
of growth factors, there was a significant increase in the percentage of KO hepatocytes 
proliferating in comparison to the WT with approximately 50% of the KO hepatocytes 
proliferating compared to 10% of the WT on days 2-4 in culture (Figure 26). These results 
suggest that when growth factors are present, a maximal level of proliferation is achieved that is 
not affected by loss of LSP1 expression, however, when growth factors are absent and the 
hepatocytes should not proliferate, a lack of LSP1 expression promotes hepatocellular division.  
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Figure 25. BrdU incorporation assay in hepatocytes from WT and LSP1 KO mice cultured in 
the presence of growth factors. A. Representative images of BrdU immunohistochemistry on WT 
(left) and LSP1 KO (right) hepatocytes cultured in the presence of HGF and EGF. BrdU was added 
to the culture medium for 2-day pulses. 100x magnification. scale bar = 100μm. B. Quantification 
of BrdU positive hepatocytes cultured in the presence of HGF and EGF at Day 0-2, 2-4, and 4-6. 
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Figure 26. BrdU incorporation assay in hepatocytes from WT and LSP1 KO mice cultured in 
the absence of growth factors. A. Representative images of BrdU immunohistochemistry on WT 
(left) and LSP1 KO (right) hepatocytes cultured in the absence of HGF and EGF. BrdU was added to 
the culture medium for 2-day pulses. 100x magnification. Scale bar = 100μm. B. Quantification of 
BrdU positive hepatocytes cultured in the presence of HGF and EGF at Day 0-2, 2-4, and 4-6. 
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To determine what downstream signaling pathways are affected by the loss of LSP1 in 
the hepatocytes, we measured pERK, cyclin D1, and KSR expression in the KO and WT 
hepatocytes. In the presence of HGF and EGF, KO hepatocytes displayed increase pERK 
expression at all of the time points as well as increased KSR expression in comparison to WT 
(Figure 27A). However, cyclin D1 expression remained unchanged between the WT and KO 
hepatocytes (Figure 27A). These findings correlate with the BrdU incorporation assay in which 
there was no difference in proliferation between the WT and KO cells (Figure 25). Without HGF 
and EGF in the medium, KO hepatocytes display increased expression of cyclin D1 and pERK 
on days 4 and 6 in culture as compared to WT hepatocytes (Figure 27 B), which supports the 
BrdU proliferation data from figure 26. These results indicate the increased proliferation that 
occurs due to the loss of LSP1 expression involves an ERK dependent mechanism.  
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Figure 27. Western blot analysis of WT and LSP1 KO hepatocytes cultured in the presence 
and absence of HGF and EGF. Hepatocytes from WT and KO mice were cultured in the (A) presence 
and (B) absence of HGF and EGF and the expression of pERK (1st panel), total Erk (2nd panel), KSR 
(3rd panel) and cyclin D1 (4th panel) were analyzed by western blot. Ponceau S staining was 
utilized to ensure equal protein loading. P, hepatocyte pellet. 
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3.3.6 LSP1 transgenic mice display decreased proliferation and ERK activation following 
partial hepatectomy 
We have demonstrated a role for LSP1 in the inhibition of proliferation after PHx through 
the expression of exogenous LSP1 via hydrodynamic tail vein injection of plasmid DNA. 
However, one caveat to this experiment is the inability to study the function of LSP1 on 
proliferation at later time points following surgery since expression of the plasmid DNA only 
lasts for a short period of time. Another consideration is that although hydrodynamic injection 
has been shown to target mostly hepatocytes it is possible that other cell types of the liver had 
taken up the plasmid and contributed to the decreased proliferation of the hepatocytes. Therefore, 
we decided to create a LSP1 transgenic (TG) mouse model in which LSP1 expression is under 
the albumin promoter and alpha-fetoprotein enhancer to ensure expression only in hepatocytes. 
Using this TG model, we performed PHx and measured the number of proliferating hepatocytes 
using the proliferation marker, Ki67. There is no difference in the percentage of Ki67 positive 
hepatocytes between the WT and TG livers on day 2 following PHx, however on day 4, we see a 
significant decrease of 25% fewer hepatocytes proliferating in the TG in comparison to the WT 
as well as approximately 50 less hepatocytes per 200x field in the TG (Figure 28 A, B and C). 
By day 7 after PHx, there is no significant difference in the number of dividing hepatocytes 
between the WT and TG mice. There was no difference in the liver to body weight ratios 
between the WT and TG mice on days 2 and 4 following surgery, however we did detect a nearly 
significant decrease in the liver to body weight ratio on day 7 (p=0.051) (Figure 29). These 
results could indicate that in the hydrodynamic tail vein injection experiment the observed 
decrease in hepatocyte proliferation is not only due to hepatocytes expressing LSP1 but also due 
to the influence of LSP1 expressing NPCs on hepatocytes.  
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Figure 28. LSP1 transgenic (TG) mice display decreased Ki67 positive hepatocytes and 
decreased hepatocyte numbers on day 4 after PHx. A. Representative images of Ki67 
immunohistochemistry on wild type (WT) (left) and LSP1 TG (right) mouse livers after PHx. 200x 
magnification. Scale bar= 100μm B. Quantification of the percentage of Ki67 positive hepatocytes in 
WT and LSP1 TG mouse livers after PHx. C. Quantification of the number of hepatocytes per 200x 
field in WT and LSP1 TG livers after PHx. ** p<0.001, ***p<0.0001. 
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Next, we measured the expression of total LSP1 in the WT and TG mice by western blot. 
Total LSP1 expression was increased in the TG at all time points analyzed following PHx as 
compared to WT indicating that the LSP1 TG was expressing the transgene (Figure 30). 
 
Figure 29. Liver to body weight ratios of WT and LSP1 TG mice after PHx. Ratio of liver 
weight to body weight was taken on days 2, 4 and 7 after PHx. There is no significant 
difference in the liver to body weight ratio at any of the time points. Each time point contains 
n=3 per condition. 
Figure 30. Western blot analysis of LSP1 expression in WT and LSP1 TG mouse livers. Total 
LSP1 expression was measured at time 0 and days 2, 4, and 7 in both the WT and LSP1 TG mouse 
livers. Each lane represents a pooled lysate containing protein from 3 separate mouse livers. Ponceau 
S staining was utilized to ensure equal protein loading. 
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To determine how the increased expression of LSP1 in the TG mouse model effects 
downstream signaling pathways, we performed western blot analysis to measure the expression 
of pERK and cyclin D1 after PHx. In the TG livers, we detected decreased pERK expression at 
all of the time points as compared to WT and the ratio of pERK/ total ERK was decreased in the 
TG livers on days 2 and 4 in comparison to control. Cyclin D1 expression is decreased in the TG 
livers on day 2 following PHx but is increased in comparison to WT on day 4 and 7 (Figure 31 
A, B and C). Since the samples analyzed are whole liver cell lysates, it is possible that the cyclin 
D1 expression is increased in the other cell types and not the hepatocytes at these time points. 
We are unable to distinguish what the level of cyclin D1 expression is in the hepatocytes 
specifically. However, we could utilize immunofluoresence or immunohistochemistry to 
visualize which cells are expressing cyclin D1. Decreased pERK expression in the TG livers 
after PHx suggests that the increased LSP1 expression leads to decreased proliferation on day 4 
through an ERK dependent pathway. 
Next, we performed immunoprecipitations to determine if the expression of LSP1 affects 
the KSR and pERK complex in the TG mice following PHx. The TG mice express less KSR than 
the WT mice at all of the time points. In the TG, the strongest interaction between KSR and 
pERK occurs at time 0 whereas in the WT livers, KSR is found in complex with pERK on days 2 
and 4 after PHx (Figure 32). These results indicate that expression of LSP1 in the TG livers 
causes an increase in the baseline complex formation but disrupts this KSR, pERK, LSP1 
interaction during liver regeneration which may contribute to the decreased proliferation detected 
after PHx in the transgenic mice.  
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Figure 31. Western blot analysis of WT and LSP1 TG mouse livers after PHx. A. WT and 
LSP1 TG livers from time 0 (T0) and day 2 (D2), B. time 0 (T0) and day 4 (D4), and C. time 0 
(T0) and day 7 (D7) were analyzed by western blot for pERK (top), total ERK (2nd from top), 
cyclin D1 (3rd from top) and ponceau S staining (bottom) was utilized to ensure equal protein 
loading. Each lane represents a whole liver lysate from a separate mouse. 
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3.3.7 Hepatocytes from LSP1 transgenic mice display decreased proliferation and pERK 
expression 
The previous studies on the LSP1 TG mice after PHx were performed on whole liver tissue 
which impedes our ability to determine which cells are contributing the expression of cyclin D1 
and pERK. These studies are also confounded by the presence of the other cell types of the liver. 
Therefore, we isolated hepatocytes from the WT and TG mice and cultured the cells with and 
without HGF and EGF to determine how the expression of LSP1 in hepatocytes effects 
proliferation. Utilizing a BrdU incorporation assay, we were able to show that both in the 
presence and absence of growth factors, the TG hepatocytes display decreased proliferation in 
comparison to WT hepatocytes (Figure 33A and B). With HGF and EGF, there is a 4-fold 
Figure 32. Immunoprecipitation of KSR in WT and LSP1 TG PHx liver lysates. Top panel: 
western blot for KSR, bottom panel: western blot for pERK expression in WT and LSP1 TG PHx 
livers at time 0 and days 2, 4 and 7. Each time point represents a pooled lysate from 3 separate 
mice. 
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decrease on days 2-4 and 2.5 fold decrease on days 4-6 in the percentage of BrdU positive TG 
hepatocytes as compared to WT (Figure 33B). In the absence of growth factors, the significant 
decrease in proliferation between TG and WT hepatocytes is approximately 2.5 fold (Figure 34 
A and B). These findings suggest that LSP1 acts as a negative regulator of hepatocellular 
proliferation both in the absence and presence of growth factors.  
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Figure 33. BrdU incorporation assay in hepatocytes from WT and LSP1 TG mice cultured 
in the presence of growth factors. A. Representative images of BrdU immunohistochemistry on 
WT (left) and LSP1 TG (right) hepatocytes cultured in the presence of HGF and EGF. BrdU was 
added to the culture medium for 2-day pulses. 100x magnification. Scale bar = 100μm. B. 
Quantification of BrdU positive hepatocytes cultured in the presence of HGF and EGF at Day 0-2, 
2-4, and 4-6. 
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Figure 34. BrdU incorporation assay in hepatocytes from WT and LSP1 TG mice 
cultured in the absence of growth factors. A. Representative images of BrdU 
immunohistochemistry on WT (left) and LSP1 TG (right) hepatocytes cultured in the 
absence of HGF and EGF. BrdU was added to the culture medium for 2-day pulses. 100x 
magnification. Scale bar = 100μm. B. Quantification of BrdU positive hepatocytes cultured in 
the presence of HGF and EGF at Day 0-2, 2-4, and 4-6. 
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Next, we wanted to determine which signaling pathways may be involved in the 
decreased proliferation detected in the TG hepatocytes. Since our previous results have 
demonstrated a role for ERK in the modulation of proliferation due to LSP1, we measured pERK 
expression as well as KSR, which form the complex along with LSP1 to modulate downstream 
effects, such as proliferation. Western blot analysis shows that pERK expression is decreased in 
the TG hepatocytes at all of the time points in comparison to WT hepatocytes when cultured with 
growth factors (Figure 35A). However, the ratio of pERK/total ERK is only decreased in the day 
TG hepatocytes in comparison to the WT controls (Figure 35A). In the absence of HGF and 
EGF, pERK levels are decreased as well as the ratio of pERK/total ERK in the hepatocytes from 
the TG animals on days 4 and 6 in culture. Expression of cyclin D1, a marker of proliferation, is 
decreased in the TG hepatocytes both in the presence and absence of growth factors (Figure 35 A 
and B). KSR expression in the TG hepatocytes was greatest at time 0 but dramatically decreased 
on days 2 and 4 before increasing in both conditions on day 6 in culture. However, in the WT 
hepatocytes, KSR levels started low in the hepatocyte pellet but steadily increased until day 6 in 
culture with HGF and EGF (Figure 35A). Without growth factors, KSR expression was high in 
the WT hepatocyte pellet and on day 4 with levels decreasing on days 2 and 6 (Figure 35B). 
These results indicate that in the TG hepatocytes, increased LSP1 expression results in decreased 
KSR expression.  
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Figure 35. Western blot analysis of WT and LSP1 TG hepatocytes cultured in the 
presence and absence of HGF and EGF. Hepatocytes from WT and TG mice were cultured in 
the (A) presence and (B) absence of HGF and EGF and the expression of pERK (1st panel), 
total Erk (2nd panel), KSR (3rd panel) and cyclin D1 (4th panel) were analyzed by western 
blot. Ponceau S staining was utilized to ensure equal protein loading. P, hepatocyte pellet. 
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3.4 DISCUSSION 
 
Our findings in Figure 14 demonstrate that loss of LSP1 is indeed associated with enhanced 
migration and enhanced proliferation rate, as evidenced by both increases in cell numbers and a 
dramatic increase in Cyclin D1 in the rat JM1 HCC cells. We demonstrated that the loss of LSP1 
expression in hepatoma cells leads to increased ERK2 activation indicating that the observed 
increase in proliferation and migration is through an ERK2 dependent pathway. Previous 
literature has demonstrated that increased LSP1 negatively regulates migration of leukocytes and 
melanoma cell lines (75, 85, 87) and our data supports this notion in hepatocytes as well. 
Expression of LSP1 in the LSP1 deficient JM2 cell line and in mouse livers in vivo after PHx 
through hydrodynamic tail vein injection of plasmid DNA led to decreased proliferation as 
evidenced by decreased cyclin D1 levels and BrdU incorporation as well as decreased Ki67 
staining. LSP1 KO mice displayed increased proliferation on day 4 as well as increased pERK 
expression whereas the LSP1 TG mice displayed decreased hepatocellular proliferation, 
expression of pERK and liver to body weight ratios. These results corroborate a role for LSP1 in 
the regulation of hepatocellular proliferation both in vitro and in vivo. 
Cyclin D1 expression has been shown to function not only in proliferation but in the 
migration of mouse embryonic fibroblasts as well as breast cancer cells (126, 127) therefore it is 
possible that the increased cyclin D1 expression observed in our experiments may be due to 
increased migration and not simply proliferation. However, we have clearly demonstrated a role 
for LSP1 in hepatocellular proliferation in vivo with increased Ki67 positive hepatocytes and cell 
numbers following PHx in the LSP1 KO mouse model as well as the opposite with decreased 
proliferation in the LSP1 TG mice. In addition to the in vivo results, hepatocytes isolated from 
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LSP1 KO mice display increased BrdU incorporation in the absence of growth factors as well as 
increased cyclin D1 and phospho ERK expression. Increased expression of LSP1 in the TG 
hepatocytes results in decreased proliferation and cyclin D1 and pERK levels indicating that 
LSP1 functions as a regulator of hepatocyte proliferation. As with the cell line studies, all of 
these effects on proliferation appear to be through an ERK dependent signaling pathway.  
Although we observed a significant increase in the percentage of Ki67 positive 
hepatocytes after PHx in the LSP1 KO livers, the increased proliferation observed was modest 
and there was no difference in the liver to body weight ratios between the KO and WT animals. 
In addition to these results, western blot analysis also demonstrated increased expression of 
LSP1 in the KO. This is due to the KO mice being created by targeting exon 1 of the LSP1 gene 
leaving expression of the alternative isoform, S37, intact (81). Therefore, the increased levels of 
LSP1 seen in the KO are most likely caused by compensation of the remaining isoform, S37 and 
this could contribute to the modest increase in hepatocellular proliferation as well as the lack of a 
difference in the liver to body weight ratios. Inhibition of the S37 isoform through shRNA could 
result in a greater increase in hepatocyte proliferation during liver regeneration in the KO mice.  
In the experiments with WT and TG hepatocytes, in the absence of growth factors, the 
percentage of proliferating WT hepatocytes was 40% as compared to 80% in the cultures 
containing growth factors.  Although the percentage of BrdU positive hepatocytes is 2 fold less, 
in the absence of growth factors, the numbers are higher than we would expect. (Figure 34B) 
One explanation may be that other components of the medium are able to promote proliferation 
in the hepatocytes of this mouse strain, C57/Bl6, versus other mouse strains such as, 129/svJ and 
FVB. Another possible reason for the increased proliferation in the WT hepatocyte cultures 
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without HGF and EGF may be that contaminating non-parenchymal cells may be present and 
expressing growth factors promoting hepatocyte proliferation.  
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4.0  SUMMARY 
There have been several recent studies identifying point mutations and large deletions in HCC 
(72). Driver and “passenger” mutations have been identified and correlated with HCC outcomes. 
Large size copy number variations (CNV: deletions or amplifications) have also been identified 
(72). We had concentrated our study (74) in identifying small size CNVs that would otherwise be 
missed in investigating approaches that would detect CNV of only large size. The latter would be 
likely to contain many genes in each CNV, thus making it difficult to identify the specific genes 
whose smaller size CNV would affect neoplastic behavior. LSP1 had the largest number of CNV 
(51 of 98 cases) (74). In view of this, we believe that elucidation of its function in normal 
hepatocyte biology is important. We do not believe that genomic alterations in LSP1 alone 
would be necessarily sufficient to drive a hepatocyte into neoplasia. The high frequency of the 
LSP1 CNV, however, suggests LSP1 loss of function is important, and that, along with other 
genomic changes, LSP1 certainly adds to the neoplastic behavior and may be sufficient to 
convert a low level neoplastic clone into one of a higher malignant potential. 
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Figure 36. Schematic of LSP1, KSR, ERK interaction in the cell. LSP1 binds to the F-actin filaments 
and KSR. KSR acts as a scaffold for the ERK signaling cascade by binding to Raf, MEK and ERK kinase. 
LSP1 acts to locate the ERK signaling complex to the actin cytoskeleton of the cell. We hypothesize that ERK 
localization to the cytoskeleton by LSP1 in our system results decreased proliferation and migration however 
the absence of LSP1 allows ERK to escape binding to the cytoskeleton and can promote migration and 
proliferation. 
 
 Previous literature has demonstrated that in hematopoietic cells LSP1 interacts with KSR 
and the Raf, MEK and ERK signaling proteins. LSP1 functions to target the MAPK pathway to 
the actin cytoskeleton of these cells through its F-actin binding domain in the C-terminal region 
of the protein (102). LSP1 is also known to function as a negative regulator of migration in 
neutrophils (86). Our data demonstrates that loss of LSP1 expression leads to increased 
proliferation and migration in hepatoma cell lines as well as during liver regeneration. One 
possible explanation for the role of LSP1 in these cellular functions is that LSP1 acts to 
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negatively regulate ERK activity. We have shown that loss of LSP1 expression leads to 
increased ERK phosphorylation whereas overexpression of LSP1 causes the opposite 
phenomenon. One hypothesis is that LSP1 in conjunction with KSR acts as a scaffold for the 
ERK signaling cascade and functions to sequester ERK at the cytoskeleton, preventing ERK 
from translocating to the nucleus and activating transcription of targets involved in proliferation 
and migration of the cell. (Figure 36) To test this hypothesis, we could perform 
immunofluorescence in our LSP1 shRNA stable cell line to detect where pERK is localized in 
comparison to scrambled controls or we could fractionate the cell to isolate the cytoskeletal 
fraction as well as the nucleus to determine if loss of LSP1 leads to increased pERK in the 
nucleus.  
In summary, LSP1 is expressed at the time of cessation of growth in hepatocytes in 
culture and increases gradually toward the end of liver regeneration. LSP1 functions as a 
regulator of hepatocyte proliferation and migration most likely by interacting and negatively 
regulating the function of the ERK/MAPK scaffold KSR. Our studies with LSP1 knockout and 
transgenic mouse models have demonstrated a role for LSP1 in liver regeneration. Future studies 
are aimed at elucidating if loss and overexpression of LSP1 will affect liver carcinogenesis in 
vivo as well as the role LSP1 may play in HCC sensitivity to sorafenib. Understanding the 
function of LSP1 in liver regeneration and cancer may lead to the development of novel targeted 
therapies for HCC.  
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5.0  FUTURE DIRECTIONS 
Future studies aim to address the role of LSP1 in hepatocarcinogenesis since our studies stem 
from the finding that in HCC LSP1 has the most CNV cases. We have clearly demonstrated that 
LSP1 functions to negatively regulate the proliferation of hepatocytes both in culture and during 
liver regeneration therefore, we hypothesize that loss of LSP1 expression in hepatocytes could 
lead to a neoplastic phenotype with increased proliferation and metastasis whereas increased 
LSP1 expression would have a protective effect against hepatocarcinogenesis. We plan to inject 
both the LSP1 knockout and transgenic mice with diethylnitrosamine (DEN), a complete 
carcinogen in that at low doses it induces carcinogenesis initiation and higher doses leads to 
promotion and progression, in order to induce carcinogenesis in the liver (128, 129). We would 
expect that the LSP1 knockout mice would have larger tumors since LSP1 inhibits proliferation 
in hepatocytes whereas in the transgenic animals, we would observe smaller tumors. One caveat 
to this experiment is that LSP1 may affect the level of cytochrome P450 enzyme expressed by 
the hepatocytes, which would affect the metabolism of DEN (129). Therefore, we must measure 
the level and activity of the Cyp enzymes in order to ensure equal activity and expression of 
these proteins in both sets of animals.   
Another possibility is that loss of LSP1 expression is an event that occurs during liver 
fibrosis and cirrhosis and before the liver tumor forms. Therefore, it would be important to study 
the role of LSP1 in liver fibrosis by using the carbon tetrachloride model to induce liver fibrosis 
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in the LSP1 KO and TG animals. If LSP1 plays a role in the development and progression of 
fibrosis, we hypothesize that loss of LSP1 would lead to increased fibrosis whereas the LSP1 TG 
mice would display a decrease in fibrosis since LSP1 functions as a negative regulator of 
proliferation and migration, which are hallmarks of stellate cell activation to the myofibroblast 
phenotype. (130) 
Genome wide associate studies in breast cancer samples have demonstrated that single 
nucleotide polymorphisms (SNPs) in LSP1 are associated with increased susceptibility to breast 
cancer. (131) This suggests that LSP1 may play in important role in the carcinogenesis of not 
only liver but other tissues as well. It may be useful to screen other cancers to determine if CNV 
or SNP of LSP1 is detectable in these other tumor types and to determine if LSP1 functions as a 
negative regulator of proliferation and migration in these cancers. It is important to understand 
the role of LSP1 in carcinogenesis in order to develop novel therapeutics that can target this 
important signaling molecule not only in HCC but other cancers as well. 
In addition to studying the role of LSP1 on the development and progression of HCC, we 
plan to investigate using LSP1 expression status in liver tumors as a diagnostic tool for a 
personalized medicine approach to treating HCC.  Since our data has demonstrated that loss of 
LSP1 expression leads to increased activity of the ERK kinase signaling pathway, it is 
conceivable that these LSP1 negative tumors would be more sensitive to inhibitors that target the 
MAPK/ERK signaling pathway, such as sorafenib (132). Sorafenib is currently the only FDA 
approved multikinase inhibitor for treatment of advanced HCC (46). In a phase III clinical trial, 
the median overall survival of patients on sorafenib increased by 3 months in comparison to 
placebo (68). However, patients were not screened to determine which would have a positive 
outcome with sorafenib. We believe patient’s tumors should be screened for LSP1 or pERK 
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expression and the efficacy of sorafenib on tumors both with and without LSP1 expression 
should be assessed. We hypothesize that the tumors lacking LSP1 expression would respond 
better to sorafenib since tumors expressing LSP1 would most likely not have increased ERK 
activation and therefore not respond as well to sorafenib treatment. Preliminary results 
demonstrate that the LSP1 shRNA expressing JM1 hepatoma cells, which express higher levels 
of ERK phosphorylation, are more sensitive to sorafenib than the scrambled control cells (Figure 
37). 
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Figure 37. Treatment of LSP1 shRNA JM1 stable cells with sorafenib causes increased cell 
death in comparison to scrambled control cells. A. Representative phase contrast images of 
scrambled shRNA control and LSP1 shRNA JM1 cells treated with DMSO (control) (Top) or 20μM 
sorafenib for 48 hours. Scale bar = 10μm. B. Quantification of the amount of DNA (μg/μl) per 
plate for scrambled control and LSP1 shRNA JM1 cells treated with DMSO and sorafenib (20μM) 
for 48 hours. 
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LSP1 is a known regulator of migration and our data demonstrates that LSP1 functions to 
negatively regulate migration in hepatoma cell lines. However, we have not studied the role 
LSP1 plays on migration in vivo which is technically challenging in a PHx model of liver 
regeneration. One method to circumvent this challenge is to utilize a different model of liver 
regeneration, the carbon tetrachloride model (CCl4), which causes the death of the hepatocytes 
around the central vein because only these hepatocytes express the enzyme that activates CCl4 to 
its toxic form, CYP2E1. The remaining hepatocytes proliferate to restore the necrotic region and 
liver architecture is intact after about 10 days (133). Hoehme, et al. demonstrated through 
mathematical modeling as well three dimensional reconstruction that during regeneration after 
CCl4 administration, daughter hepatocytes migrate into the necrotic region and align along the 
sinusoids and that this phenomenon is necessary to restore normal liver microarchitecture (133). 
Therefore, using this model, we can determine if loss of LSP1 expression can lead to increased 
hepatocyte migration into the necrotic region created in the pericentral region of the liver by 
CCl4 administration. 
Another area of LSP1 research that needs to be explored further is the function of the 
different isoforms of LSP1 in our model system. It is conceivable that one of the isoforms 
functions to regulate proliferation while the other plays a role in migration since cells that are 
dividing are not migrating and vice versa. To test this hypothesis, we could overexpress each 
isoform of LSP1 in our JM2 hepatoma cell line and measure the effect on proliferation and 
migration of these cells. Since isoform 1 of LSP1 is the isoform deleted in the LSP1 KO animals 
and overexpressed in the LSP1 TG animals and we have demonstrated an effect on proliferation 
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during regeneration, we would expect that isoform 2 (S37) functions as the negative regulator of 
migration.  
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